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Abstract 
 The objectives of this research project were to (i) synthesize different bicyclic and 
tricyclic pyrone and pyridinone compounds; (ii) study the mechanism of action of these 
compounds in solution as anti-Aβ (amyloid β) agents using different biophysical techniques; and 
(iii) study the biological activity of pyrone compounds for the counteraction of Aβ toxicity using 
MC65 cells, a human neuroblastoma cell line and 5X- familial Alzheimer’s disease (5X FAD, a 
transgenic mice with five different mutations) mice. 
A series of tricyclic pyrone and pyridinone compounds were investigated. The tricyclic 
pyrones and pyridinones were synthesized utilizing a condensation reaction between 
cyclohexenecarboxaldehye (25) and 4-hydroxy-6-methyl-2-pyone (24) or 4-hydroxy-6-methyl-2-
pyridinone (51), respectively. A tricylic pyrone molecule CP2 (2, code name) was synthesized 
and has an adenine base unit attached to the pyrone core. For structure activity relationship 
(SAR) studies, the adenine group of CP2 was replaced with other DNA base units (thymine, 
cytosine and guanine) and various heterocyclic moieties. Since nitrogen containing compounds 
often exhibit increased bioactivity and brain-penetrating abilities, oxygen atom (O5’) was 
displaced with a nitrogen atom in the middle ring of the tricyclic pyrone. A condensation 
reaction of pyrone 51 and 25 was carried out to give the linear pyranoquinoline (52) and the L-
shaped pyranoisoquinoline (53).  
The neurotoxicity of amyloid-β protein (Aβ) is widely regarded as one of the fundamental 
causes of neurodegeneration in Alzheimer’s disease (AD). Recent studies suggest that soluble 
Aβ oligomers rather then protofibrils and fibrils may be the primary toxic species. Different 
biophysical techniques including atomic force microscopy (AFM), circular dichroism (CD), 
surface plasmon resonance (SPR) spectroscopy, and protein quantification assays were used to 
study the mechanism of aggregation of Alzheimer Aβ peptide in solution.  
In search of potentially bioactive compounds for AD therapies, MC65 cell line was used as 
a screening model. Different tricyclic pyrone and pyridinone compounds protect MC65 cells 
from death. We studied the efficacy of CP2 in vivo by treatment of 5X FAD mice, a robust 
Aβ42-producing animal model of AD, with a 2-week course of CP2, which resulted in 40% and 
50% decreases in non-fibrillar and fibrillar Aβ species respectively. 
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Abstract 
The objectives of this research project were to (i) synthesize different bicyclic and tricyclic 
pyrone and pyridinone compounds; (ii) study the mechanism of action of these compounds in 
solution as anti-Aβ (amyloid  β) agents using different biophysical techniques; and (iii) study the 
biological activity of pyrone compounds for the counteraction of Aβ toxicity using MC65 cells, a 
human neuroblastoma cell line and 5X- familial Alzheimer’s disease (5X FAD, a transgenic 
mice with five different mutations) mice. 
A series of tricyclic pyrone and pyridinone compounds were investigated. The tricyclic 
pyrones and pyridinones were synthesized utilizing a condensation reaction between 
cyclohexenecarboxaldehye (25) and 4-hydroxy-6-methyl-2-pyone (24) or 4-hydroxy-6-methyl-2-
pyridinone (51), respectively. A tricylic pyrone molecule CP2 (2, code name) was synthesized 
and has an adenine base unit attached to the pyrone core. For structure activity relationship 
(SAR) studies, the adenine group of CP2 was replaced with other DNA base units (thymine, 
cytosine and guanine) and various heterocyclic moieties. Since nitrogen containing compounds 
often exhibit increased bioactivity and brain-penetrating abilities, oxygen atom (O5’) was 
displaced with a nitrogen atom in the middle ring of the tricyclic pyrone. A condensation 
reaction of pyrone 51 and 25 was carried out to give the linear pyranoquinoline (52) and the L-
shaped pyranoisoquinoline (53).  
The neurotoxicity of amyloid-β protein (Aβ) is widely regarded as one of the fundamental 
causes of neurodegeneration in Alzheimer’s disease (AD). Recent studies suggest that soluble 
Aβ oligomers rather then protofibrils and fibrils may be the primary toxic species. Different 
biophysical techniques including atomic force microscopy (AFM), circular dichroism (CD), 
surface plasmon resonance (SPR) spectroscopy, and protein quantification assays were used to 
study the mechanism of aggregation of Alzheimer Aβ peptide in solution.  
In search of potentially bioactive compounds for AD therapies, MC65 cell line was used as 
a screening model. Different tricyclic pyrone and pyridinone compounds protect MC65 cells 
from death. We studied the efficacy of CP2 in vivo by treatment of 5X FAD mice, a robust 
Aβ42-producing animal model of AD, with a 2-week course of CP2, which resulted in 40% and 
50% decreases in non-fibrillar and fibrillar Aβ species respectively. 
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CHAPTER 1 - Synthesis of tricyclic pyrone and pyridinone 
compounds 
1.1 Introduction 
 
Neurodegenerative diseases1 including Alzheimer’s disease (AD),2 Huntington’s disease 
(HD),3 Parkinson’s disease,4 amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease)5 and 
prion diseases6 involve protein misfolding which produce aggregates in different regions of the 
brain. It has been observed that different neurodegenerative diseases have different protein 
aggregates and pathologies as described in Table 1.1.7 Alzheimer’s disease (AD) is a 
neurological protein misfolding disease and is the fourth leading cause of death. It is 
characterized by progressive dementia that leads to incapacitation and death. It includes synaptic 
loss and neuronal death, which over course of time is responsible for the loss of memory, 
personality and eventual death.8 AD affects 15 million people worldwide, and its incidence 
increases from 3.5% per year at age 65 to 19% at age 85 and to 47% over 85 years old.8 To date, 
there is no successful treatment for AD patients. In this chapter I will discuss the synthesis of 
different tricyclic pyrone and pyridinone compounds and evaluate their bioactivities for 
counteracting AD protein misfolding. 
  
1.2 Background 
 
Alzheimer’s disease involves protein misfolding and is a progressive and irreversible 
brain disorder with no cure. There are two characteristic neuropathological lesions that define 
AD namely, (i) extracellular plaques, also called amyloid plaques which are mainly composed of 
amyloid beta (Aβ) peptides consisting of 39-43 amino acids, proteolytic cleavage products from 
amyloid precursor protein (APP)9; and (ii) intracellular tangles, also called neurofibrillary tangles  
(NFT), which are aggregates of Aβ and microtubule associated tau protein.10 
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The Aβ peptide segment is generated by the endoproteolysis of APP transmembrane 
protein by beta (β) and gamma (γ) secretase enzymes.11 APPs are synthesized as N- and O- 
glycosylated integral transmembrane protein. They have a large amino (NH2) terminal 
extracellular domain and a short 47 amino acids long cytoplasmic domain.12 The biological 
function of APP is unknown and it hinders the understanding of pathophysiology of AD. 
Suspected functions of APP include inhibition of extracellular serine proteases,13 involvement in 
cell adhesion14, and synaptic plasticity.15 APP may function as a cell receptor.16  
Firstly, APP is first cleaved by α- or β- secretase. α- Secretase cuts close to 
transmembrane domain, in the middle of the Aβ region of APP (Figure 1.1) and a a-APP 
ectodomain and a 83-residue carboxy terminal (C83) fragment is formed.   On the other hand, β- 
secretase enzyme cleaves the APP forming β-APP ectodomain and a 99-residue carboxy terminal 
(C99) fragment. Proteolysis of C99 peptide residue fragment by gamma- (γ) secretase enzyme 
produces the heterogeneous Aβ (39-43 amino acids) peptide as shown in Figure 1.1.17 
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Disease Etiology Regions affected Characteristic   
pathology 
Disease protein 
deposited 
Alzheimer’s 
disease 
1.Amyloid 
precursor protein 
2. PS1 and PS2 
3.Sporadic 
(ApoE risk 
factor) 
Cortex, 
hippocampus, 
basal forebrain, 
brain stem  
Neuritic plaque 
and 
neurofibrillary 
tangles. 
Aβ peptide and 
hyperphosphorolated 
tau protein. 
Huntington’s 
disease 
Huntingtin 
(dominant) 
Protein 
Striatum, other 
basal ganglia 
Intracellular 
inclusions 
Huntingtin with 
polyglutamine 
expansion 
Parkinson’s 
disease 
Sporadic 
α-Synuclein 
Cortex, substantia 
nigra, locus 
ceruleus 
Lewy bodies and 
lewy neurites 
α-Synuclein 
Amyotropic 
lateral 
sclerosis 
(ALS) 
Sporadic 
Superoxide 
dismutase-1 
Same as sporadic Bomina bodies 
and axonal 
spheroids 
Unknown 
Prion disease Sporadic, genetic 
and infectious 
Cortex, thalamus, 
brain stem, 
cerebellum, other 
areas 
Spongiform 
degeneration 
amyloid, other 
aggregates 
Prion protein 
Table 1.1. Neurodegenerative diseases: protein and pathology.7 
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Figure 1.1. Proposed pathway of generation of Aβ peptide. (modified from reference 18 without 
the Author’s permission) 
  
 
Although the detailed mechanism of aggregation and its causes in brain remain unknown, 
extensive research has been conducted and it is widely accepted that Aβ monomer is non-toxic, 
soluble and possess random coil/ alpha helix secondary structure. These Aβ monomeric species 
can undergo physiological changes/ conformation changes and aggregation to form soluble 
oligomers (5-10 nm diameter and 6 nm height) and protofibrils (~180 nm length). The soluble 
oligomers undergo nucleation polymerization to form protofibrils and insoluble fibrils (Figure 
1.2).18 Recent studies have shown that soluble Aβ oligomers, rather than insoluble Aβ fibrils are 
the primary toxic species in AD.19 Hence, the conversion of Aβ from a soluble, monomeric form 
to a soluble, aggregated forms appears to be the initial process of amyloid neurotoxicity. It is also 
  5 
hypothesized that the intraneuronal accumulation of Aβ is the first step of the amyloid cascade.20 
Also it has been proved that intracellular Aβ induces a higher toxicity, being at least 10,000 
times more toxic than extracellular Aβ.21  
 
Small Aβ 
oligomers
Monomeric
     Aβ
Aβ ProtofibrilsLarge Aβ oligomers
Aβ Fibrils  
Figure 1.2. Proposed mechanism of Aβ aggregation from monomers to fibrils. (Modified from 
reference 18 without the author’s permission) 
 
Aβ oligomers and protofibrils are highly neurotoxic, even in nanomolar concentrations, 
in vitro.21 Aβ42 is more toxic and tends to aggregate faster than Aβ40 due to its hydrophobicity. 
The following diagram shows the hydrophobicity indexes of the Aβ(1-42) peptide segment. The 
more positive units refer to the more hydrophobic β-sheet forming fragments. The more negative 
units refers to the more hydrophilic fragments (Figure 1.3).22 
 
 
Figure 1.3. The hydrophobicity indexes of amyloid (1-42) sequence. (Modified from reference 
22 without the author’s permission) 
 
Although the elucidation of the genetic, biochemical and biophysical origin of AD is very 
complex, a number of factors have been determined to be involved in neuronal damage. 
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Alzheimer’s disease occur in two forms: (1) the rare, early onset familial AD (FAD), an 
autosomal disorder caused by mutations in APP, presenilin1 (PS1) and presenilin 2 (PS2) 
membrane proteins. (2) A common sporadic non-familial AD, which results in the generation of 
Aβ42.23 Presenilins (PS1 and PS2) are integral membrane proteins with six to eight 
transmembrane domains. PS are mainly localized in the Endoplasmic reticulum (ER) and Golgi 
system.24 Presenilin 1 (PS1) is believed to be an important component of the γ-secretase 
complex. Mutations in PS1 result in over production of the Aβ42.25 The toxicity of Aβ peptide 
also includes individual or combinations of apoptosis26 and the disruption of calcium ion 
homeostatis,27 toxic radicals,28 metal ions,29 pH30 etc as depicted in Figure 1.4.  
 
 
 
Figure 1.4. Contributing factors promoting Aβ aggregation and neuronal damage. 
 
Recent studies have linked the Aβ aggregation with apolipoprotein E (ApoE).31-32 ApoE 
is a 34 KDa (~299 amino acids) lipid transport protein, which is synthesized in liver and brain. It 
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exists in three isoforms in the human population, ApoE2, ApoE3 and ApoE4. In central nervous 
system ApoE is a common apolipoprotein in cerebrospinal fluid (CSF) and is secreted by glia 
cells in a high-density lipoprotein (HDL) like particle.33 Strittmatter et al. showed that E4 allele 
of ApoE is a genetic risk factor of late onset Alzheimer’s disease (LOAD).34 The interaction of 
ApoE and Aβ was suggested when ApoE immunoreactivity was detected in extracellular 
amyloid deposits in AD brain. Recently, binding of the C-terminus residue of ApoE was 
observed with Aβ plaques and ApoE help to aid in the progression of small deposits to large 
deposits.35 In vitro and in vivo data suggest that ApoE interaction with Aβ can affect mechanisms 
of both clearance and deposition of Aβ.36-38 
 
It has been shown that several tricyclic pyrone (TP) compounds protect MC65 cells from 
cell death.39 The structures of TP compounds are similar to that of pyripyropene A (1),40 an acyl-
coenzyme A cholesterol O-acyl-transferase (ACAT) inhibitor (Figure 1.5). Pyripyropenes were 
isolated from Aspergillus fumigatus FO-12189 as microbial metabolites that strongly inhibit 
ACAT. ACAT is an enzyme that catalyzes intracellular esterification of cholesterol. ACAT plays 
a critical role in the events that are contributing to atherosclerosis. Inhibitors of ACAT hold a 
promise as antiatherosclerotic agents. Recently, there is a growing body of evidence that links 
cholesterol to the development of Alzheimer’s disease.41,42 It has been showed that animals fed 
with cholesterol rich diets exhibit increased levels of Aβ over the normal or low cholesterol 
diet.43 In vivo studies also support the above theory as increased cellular cholesterol levels result 
in the increase of Aβ production in rabbits and mouse models.44 It was found that 
hypercholesterolemia induced by high cholesterol diet accelerated the Aβ deposition in APP-
transgenic mice model of AD.44 Refolo. et.al. reported that a cholesterol lowering drugs that 
inhibits 7-dehydrocholesterol-reductase enzyme (this enzyme increases the cholesterol 
biosynthesis), reduces the Aβ deposition in APP transgenic mice model.44 Studies have been 
carried out on the interaction of Aβ with the plasma membranes, lipids including cholesterol and 
fatty acids.45,46 Binding of Aβ to the lipids is dependent on the aggregation state of Aβ i.e. 
monomeric Aβ does not bind to the lipids, and aggregated form of Aβ was found to bind to 
lipids.46 On the other hand, different groups have investigated the modulation effect of 
cholesterol on the interaction of Aβ and neuronal cell surface.47-49 Probst et al. suggested that the 
initial deposition of Aβ occurs on the neuronal plasma membrane.50 Later, Mori et al. found the 
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abnormal accumulation of cholesterol in Aβ plaques and suggested that cholesterol plays an 
important role in the formation of senile plaques.51 Based on these findings, we synthesized and 
screened a number of tricyclic pyrone analogs, and discovered that a small molecule named CP2 
(2) can protects MC65 cells from cell death. Synthesis of these tricyclic pyrone derivatives 
originated from our initial plan of synthesis of pyripyropenes. CP2 was found to be lipophilic 
and cell permeable with the ability to block Aβ aggregation and disaggregates toxic Aβ 
oligomers and protofibrils to non-toxic monomers in solution.39, 52-54 
 
O
O
O
N
N N
N
NH2
O
O
O N
OAc
HO
AcO H
AcO
Pyripyropene A (1)  CP2 (2)  
Figure 1.5. Structure of pyripyropene A and CP2. 
 
1.2.1 Reported small compounds with potential Anti-Aβ   activity 
 
In the past decade, different organic compounds have been studied for the inhibition of 
aggregation of amyloid Aβ peptide as a therapeutic strategy for the treatment of AD. It includes 
apomorphine (3),55 curcumin (4),56 porphyrins (5),57 congo red (6)58, and Cu/Zn chelators such as 
Clioquinol, a 5-chloro-7-iodo-8-hydroxyquinoline (7)59. Congo red was the first reported small 
molecule to bind to the amyloid plaque. These compounds and their various analogs have shown 
to inhibit Aβ aggregation. Although the mechanism of inhibition of aggregation is still unknown, 
many reported small molecules inhibitors share a structural similarity i.e. planarity and 
aromaticity that allows the alignment with the β-sheet structure (Figure 1.6). Current research is 
also looking at metal mediated oxidative stress.60,61 Abnormal levels of Cu, Zn and Fe have been 
reported in different parts of brain in neutrophil and plaque of a brain with AD. Concentration of 
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metal is 3-5 folds in AD patients when compared to a normal brain.62 Iron, copper and zinc have 
shown to enhance toxicity in in vitro Aβ cultures.63,64 It has been observed that Aβ peptides exert 
toxicity due to generation of cellular hydrogen peroxide, which facilitates apoptosis in neuron 
cell cultures.65 Toxicity due to generation of H2O2 was confirmed by addition of catalase 
enzyme, which converts H2O2 to water.66 It has been found that addition of Cu/Zn or Fe in 0.1-
5mM initiate seeding of Aβ which induces aggregation. Resolubilzation of Aβ plaque from the 
postmortem AD brain has also been reported using metal chelators.67 Since metals interact with 
Aβ peptide and induce aggregation, ligands with intermediate affinity can be utilized to bind to 
the metal atom and thus disrupt the metal protein interactions responsible for Aβ aggregation. 
Clioquinol, a 5-chloro-7-iodo-8-hydroxyquinoline  (CQ) has shown to have strong complexation 
with Cu and Zn thus has shown promising results (Phase II clinical trails) towards AD therapy.59 
 
H2N
SO3Na
NH2
NaO3S
N
HO
HO H H3CO
HO
O OH
OCH3
OH
3. Amorphine 4. Curcumin
5. porphyrin
6. Congo red
7. Clioquinol
N
Cl
OH
I
CH2OH
OH
OHHOH2C
HOOC COOH
Fe
+3
Cl
 
Figure 1.6. Reported organic compounds with anti-AD activity. 
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1.2.2 Natural bioactive compounds with lactone core 
 
Tricyclic pyrone molecule CP2 has pyran functionality, and it exists in a range of 
biologically active compounds. Arisugacins A (8) and B (9) metabolites, structurally similar to 
pyripyropenes, are extracted from the culture broth of Penicillium sp. and possess potent and 
selective acethlcholinesterage (ACHE) inhibitory activities. The IC50 of arisugacins A and 
arisugacins B is 1 nM and 26 nM respectively.68-69 
 
O
O
O
O
OH
OH
OCH3
H
8 Arisugacin A; R = H
O
O
O
O
OH
OH
OCH3
OMe
9 Arisugacin B; R = OMe  
Figure 1.7. Bioactive microbial metabolites possessing pyran functionality. 
 
Over the past 15 years, a number of engineered aromatic polyketides (figure 1.8) have 
been synthesized by using enzyme subunits (polyketides synthase enzymes; PKSs). These 
natural polyketide compounds have different structural backbones, but all contain 4-hydroxy-6-
methyl-2-pyrone functionality.70 These engineered polyketides can be viewed as a library of 
aromatic pyrones, which can be used for the synthesis of different bioactive compounds of 
medicinal interest.70 Ridley et al. synthesized a series of polyketides from the compounds shown 
in Figure 1.9 by exploiting their pyrone core moiety, which was condensed with different α,β-
unsaturated aldehyde (17, 18 and 19). Rearrangement proceeds via a Knoevenegal 6π- 
electrocyclic ring closing reaction mechanism, whereby the amine-activated aldehyde undergoes 
a nucleophilic attack by the pyrone. Novel engineered pyranopyrones (Figure 1.9) were 
evaluated as tumor inhibitors in three different cell lines.70 Hua et al. also reported the synthesis 
of a library of tricyclic pyranopyrones and found that only tricyclic pyrone with pyridine ring at 
position C11 are toxic to cells (structurally similar to arisugasin) and thus studied for 
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acetylcholinesterase (AChE) inhibitory activity whereas methyl group at C11 position are 
completely non-toxic to cells.71 
O
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HO
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O
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O
HO
O
OH
HO
O O
HO
O
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OH
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O
10 Mutactin 11 SEK4 12 SEK15
14 RM20b 15 RM80
13 SEK15b
16 PK8  
Figure 1.8. Structures of engineered type II polyketides.70 
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O
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17 18 19
20 232221  
Figure 1.9. Aldehyde used (17 - 19) and the pyranopyrones prepared (20 – 23) in this study.70 
 
1.2.3 Previous studies in our laboratory 
 
Previous studies in our laboratory have found that a tricyclic pyrone compound namely 
CP2 showed protection against MC65 cells, a human neuroblastoma cell line with IC50 = 
0.18mM.52 In our laboratory, Dr. Yi Chen72 synthesized CP2 in four steps (Scheme 1.1). 4-
hydroxy-6-methyl-2-pyrone (24) and perillaldehyde were condensed in the presence of L-proline 
and ethyl acetate to afford a tricyclic pyrone. In order to induce chirality, (S)-(-)- perillaldehyde 
(25) was employed, and when refluxed with pyrone molecule (24) and L-proline, a single 
diastereoisomer (26) of tricyclic pyrone was obtained in a 78% yield.71 The compound obtained 
was purified by crystallization from hot ethyl acetate to afford yellow needle shape crystals and 
the structure and stereochemistry at C-5 was unambiguously determine through X-ray 
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crystallography analysis.71 The mechanism for this condensation reaction has been proposed to 
take place via a 1,2 addition followed by dehydration and subsequent 6π- electrocyclic ring 
closing reaction (Scheme 1.2).71 The reason for the asymmetric induction might be from the 
isopropylene group since it needs to adopt the equatorial conformation to keep low transition 
energy, thus inducing an axial stereochemistry at C5 carbon. Selective hydroxylation of the 
terminal double bond in 26 was carried out by hydroboration followed by oxidation to yield two 
diastereomers (1:1) of alcohol (27) in a 69% yield. Mesylation of the alcohol (27) was achieved 
by treating alcohol with triethylamine and methanesulfonyl chloride to afford 28 in 94% yield. 
The mesylate 28 and adenine were taken together and heated in freshly distilled 
dimethylacetamide (DMA dried by CaH2) at 150°C for 8 h. Column chromatographic separation 
provided two diastereomeric products (2, more polar, N-3) and  (29, less polar, N-9 analog) in 
10:1 ratio respectively.52  
 
O
O
O
H
O
O
O
H
OH
O
O
O
H
OSO2CH3
O
O
O
H
N
N
N
N
NH2
O
OH
O CHO L-prolineEthyl acetate, 
reflux 8h
1. BH3.THF
  -20oC, 24h
2. H2O2, NaOH
    0oC, 2h
NEt3, MsCl, 
0oc, 2h
Adenine, DMA
150oC, 8h
O
O
O
H
N
NN
N
NH2
24 25 26 27
28 2 29
93
5
9a
10
 
Scheme 1.1 Syntheses of CP2 (code name; 2) and TP3 (code name; 29). 
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Scheme 1.2. Proposed mechanism for the synthesis of tricyclic pyrone molecule 33. 
 
A successful condensation reaction between a 4-hydroxy pyrone cyclohexen-1-
carbonaldehyde was accomplished in good yield and has substantial applicability in forming 
fused ring structures. Although there were multiple double bonds in TP structure, but selective 
hydroxylation was achieved by using 0.33 equivalents of borane and the reaction was carried out 
at low temperature. If the hydroboration was performed at room temperature both the 
isopropylene double bond and internal C9a and C10 would have been hydroxylated. 
Regiochemistry at N3 and N9 in compound 2 and 29 was unequivocally assigned with the help 
of 2D-HMBC spectroscopy, where the correlation between carbon of CH2N and adenine proton 
was observed.  
 
1.3 Results and Discussion 
 
My research project involved the synthesis and modification of tricyclic pyrones and 
pyridinones and the study of their anti-alzheimer activities. First project involved the 
modification of CP2 molecule. Our purpose is to make these tricyclic compounds more water-
soluble and to improve their biological activity. Introducing a polar group such as alcohol at C-
11 position, might improve the hydrophilicity and thus form better hydrogen bonding with the 
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Aβ peptide. Since CP2 has a stereocenter at position C-12, another modification of CP2 is to 
have a double bond at C-12 and avoid diastereomeric mixture and study its biological activity. 
Since nitrogen containing compounds often increase bioactivities and brain–penetrating ability, a 
prudent modification is the displacement of oxygen atom at position 2 and position 5 with a 
nitrogen atom. CP2 molecule has adenine unit attached to it, we want to examine the effect of 
other purine- and pyrimidine- units to the TP and their M65 cell protective activities.  
 
1.3.1 Modification at C-11 position of CP2 
 
O
O
O
12
1 2 3
4
4a10
10a
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9a
678
9
11
 
 
The first modification involved the addition of a hydroxyl group on the C-11 methyl 
group. Dr. Chen first introduced an acid group at C-11 position by treating pyrone (26) with 1.5 
equivalent of freshly prepared LDA at –78°C for 3 h. Anion formation was visible by the 
appearance of a blue color in the reaction mixture. Anion formed was stabilized by the addition 
of HMPA. The reaction mixture was stirred for 3h and the reaction was quenched by carbon 
dioxide. The product was obtained in excellent yield. Similarly, when anon was quenched by the 
addition of excess para-formaldehyde, compound (30) was obtained in 28% yield. Several 
attempts have been made to improve the yield but went in vain. The compound 30 was not stable 
at room temperature and was used quickly in the next reaction. Alcohol 30 was treated with 
acetic anhydride in pyridine at 0°C overnight to afford 31 in a 62% yield. Selective 
hydroxylation of 31 was obtained by hydroboration followed by oxidation. This afforded two 
diastereomers at C-12 of alcohol 32 in 1:1 ratio with a 56% yield. Alcohol 32 was mesylated 
using methanesulfonyl chloride and triethylamine at 0°C in 90% yield. Mesylate 33 was 
displaced with adenine by heating the reaction mixture in dry DMA in 150°C to afford 34 in 8% 
yield after purification by column chromatography (Scheme 1.3). Low yields were due to the 
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decomposition of reaction at high temperature, and no reaction was observed at a low 
temperature.72 The final step involved the removal of acetate group, but compound 34 was 
decomposed in basic conditions.   
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Scheme 1.3. Modification at C-11 methyl of CP2. 
 
1.3.2 Synthesis of CP2 analog with a double bond at C12  
 
Since CP2 compound contains two diastereomers, they were difficult to separate. We 
want to remove the stereocenter at C12 by introducing a double bond. Pyrone 26 was treated 
with SeO2 and t-butylhydrogen peroxide in methylene chloride solvent, which produced 36 with 
a  22% yield. An alternative method was employed. This method involved the treatment of 
pyrone 26 with 0.1 equivalents of palladium (II) acetate, 3 equivalents of hydroquinone, and 0.2 
equivalents of diethyl malonate, together in acetic acid solvent, which afforded compound 35 in 
a 60% yield after purification by column chromatography.74 Hydrolysis of the acetate function of 
35 was carried out using potassium carbonate in methanol at 0°C for 1h, which furnished 36 in a 
82% yield. Alcohol 36 was treated with triethylamine followed by the addition of 
methanesulfonyl chloride to obtain compound 37 in 41% yield. Displacement of the mesylate 
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moiety with adenine was obtained by heating the reaction mixture in DMA at 150°C for 8 h to 
give compound 38 in a 26% yield.75 The regiochemistry at N3 position of 38 was unequivocally 
assigned by 2D-HMBC NMR spectroscopy where a cross peak between CH2N and C2’H (δ 
8.02) was observed (Scheme 1.4). 
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Scheme 1.4. Synthesis of CP2 analog, compound 38. 
 
 
1.3.3. Synthesis of heterocyclic pyrone analogs 
 
The CP2 molecule has adenine unit attached to it. We want to examine the effect of other 
purine, pyrimidine, units and heterocyclic compounds to the TP and their M65 cell protective 
activities. Similar to CP2 synthesis, other heterocyclic TP analogs can be synthesized by treating 
mesylate (28) with other heterocyclic compounds. Yields obtained using same condition were 
moderate and required high temperatures. An alternate route was designed where alcohol 27 was 
converted to bromide (39) using PPh3 and CBr4 in 91% yield (Scheme 1.5). Adenine has a C6 
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amino electron donating effect, which leads to the nucleophilic attack at the N-3 position. 6-
chloropurine has no such electron donating effect thus no nucleophilic displacement reaction 
with bromide was observed. On the other hand, use of NaH with bromide and 6-chloropurine at 
80°C for 12 h yielded N9 analog 40 in 82% yield (Scheme 1.5).75 
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CBr4, PPh3
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80oC, 12h
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N
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6- chloropurine
40  
Scheme 1.5. Synthesis of TP analog 40. 
  
Treatment of bromide and cytosine was studied and two compounds, 41 and 42, were 
obtained. Compound 41 was the obtained in 28% yield, and the regiochemistry at N1 was 
unequivocally assigned by 2D-NOESY NMR spectroscopy where NOE correlation between 
CH2N (δ 3.93 and 3.37 ppm) and C6-H of cytosine (δ 7.21 ppm) was observed. Also, the C13 
carbon peak of CH2N in 41 is 53.9 ppm whereas the C13 carbon peak of CH2O in 42 is 69.7 ppm 
(Scheme 1.6).76,77 Other bases such as Cs2CO3 and K2CO3 were also used but no improvement in 
the yield was observed.     
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Scheme 1.6. Syntheses of TP analogs 41 and 42 
 
  19 
Using similar conditions, other heterocyclic analogs were synthesized from 3-amino-
pyrazole-4-carbonitrile, 2-mercaptopyrimidine, thymine, and guanine respectively. The separate 
displacement reaction of bromide 39 with 3-amino-pyrazole-4-carbonitrile, 2-
mercaptopyrimidine, thymine and acetylated guanine with sodium hydride afforded displacement 
products 43, 44, 45 and 46 respectively. The N1 regiochemistry of 43 was unequivocally 
assigned by NOE spectroscopy.78 Treatment of bromide and 2-mercaptopyrimidine with NaH 
was carried out and compound 44 was obtained, which is consistent to the reported literature.79 
(Scheme 1.7) 
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Scheme 1.7. Syntheses of TP analogs 43, 44, 45 and 46. 
 
Similarly, the N1 regiochemistry of 45 was unequivocally assigned by NOE 
spectroscopy. NOE correlation was observed between the CH2N (δ 3.82 and 3.40 ppm) and the 
C6-H of thymine (δ 6.94 ppm).80 Treatment of bromide (39) and guanine with 1 equivalent was 
studied, and to our surprise, no product was obtained. When heated at high temperature, the 
starting material was decomposed and bases other than NaH were used but no product was 
isolated. The literature has shown some evidence that in order to obtain N9 alkylation, we have 
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to protect the C2 amino group of guanine.81-82 N9-alkylated product 46 was isolated with a 15% 
yield when N2-acetylated guanine and NaH when treated with bromide. NOE correlation was 
observed between the CH2N  (δ 4.46 and 4.03 ppm) and C8-H (δ 7.73 ppm) proton (Scheme 
1.7). 
 
Compound 47 has a structure similar to CP2 but is fluorescent in nature thus can be used 
for staining of plaques with fluorescence microscopy. No displacement reaction of 2-
aminopurine and bromide was observed, when no base was used. Different bases were used and 
Cs2CO3 yielded the compound 47 in 48% yield. The N9 regiochemistry was assigned by NOE 
correlation between the CH2N ((δ 4.10 and 3.89 ppm) and the C8-H proton ((δ 7.71 ppm) and no 
correlation was observed between CH2N and C6-H proton (Scheme 1.8).83    
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Scheme 1.8. Synthesis of TP analogs 47. 
  
The amine group is a polar group and is known to be important in lots of compounds. 
Therefore, efforts were made to attach an amino group directly to the tricyclic pyrone core. Dr. 
Yi Chen did it by selective hydroxylation of tricyclic pyrone 26 followed by oxidation to 
produce 27. Mesylation, nucleophilic substitution and reduction of azide were carried out and the 
desired amine 48 was obtained. We are interested in this amine moiety because various polar 
heterocyclic aldehydes can be coupled to the tricyclic pyrone core. An alternative route to the 
amine synthesis was followed. The desired amine was obtained, which is being used to 
synthesize different analogs, by treating the tricyclic pyrone with BH3•THF and in situ refluxing 
with hydroxylamine-O-sulfonic acid (Scheme 1.9).  
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Scheme 1.9.Synthesis of TP analog 48. 
 
1.3.4 Synthesis of pyrone compounds having nitrogen in middle ring: 
pyranoquinolinone and pyranoisoquinonlinone compounds  
 
Since nitrogen containing compounds often exhibit increased bioactivity and brain-
penetrating abilities, only O5’-analogs have been synthesized in our laboratory. Another prudent 
modification with a potentially interesting anti-Alzheimer activity would involve the 
displacement of the oxygen atom (O5’) with a nitrogen atom in the middle ring of tricyclic 
pyrone. Dr. Chen synthesized 4-amino-6-methyl-2-pyrone (51) from 4-hydroxy-6-methyl-2-
pyrone (24) in three steps (Scheme 1.10).84 He was interested in expanding the application of 
new condensation reaction (Scheme 1.2) towards the synthesis of biologically potent 
compounds. Compound 24 was stirred in DMF. Then PBr3 in diethyl ether was added dropwise 
with constant stirring at 0°C followed by heating the reaction mixture at 60°C overnight. This 
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yielded compound 49, which was purified by column chromatography (81% yield).84 The 
bromide was converted to azide by its treatment with sodium azide in DMF at 0°C followed by 
column chromatography which afforded compound 50 in a 80% yield. Reduction of azide 50 to 
amine 51 was achieved by treating the azide with Pd/C in ethanol at room temperature to form 
the product in a quantitative yield.84 To their surprise, when amine 51 and cyclohexene-2-
carbonaldehyde was refluxed in ethyl acetate, no reaction was observed. Several other attempts 
have been made but in vain.  Eventually, a successful condensation reaction between amine (51) 
and aldehyde was observed in 0.1 equivalents of (S)-(+)-10-camphorsulfonic acid to give a 
mixture of linear tricyclic pyranoquinoline (19%) and L-shaped pyranoisoquinoline (48%). We 
extended the application of the reaction by using amine 51 and (S)-(-)-perillaldehyde (25) and 
(d)-camphor sulfonic acid, using toluene as a solvent and heated to 85°C for 3 days. This 
resulted in the formation of two compounds (52 and 53) in 1:1 ratio, which were separated by 
column chromatography in 36% yield (Scheme 1.10).75 
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Scheme 1.10. Synthesis of pyranoquinolinone 52 and pyranoisoquinonlinone 53. 
  
The reaction proceeds in two different pathways for the formation of 52 and 53. The 
proposed mechanism for the formation of 52 is same as that of tricyclic pyrone. The 
condensation reaction has been proposed to take place via a 1,2 addition followed by dehydration 
and subsequent 6π- electrocyclic ring closing reaction. Compound 53 involved the imine 
formation followed by 6π- electrocyclic ring closing reaction (Scheme 1.11).   
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Scheme 1.11. Proposed mechanism for synthesis of 53. 
  
1.3.5 Synthesis of novel pyranopyridinone analogs (N2’-analogs) 
 
Water solubility is an important factor for any compound to be used in a biological 
system. With this aim in mind, an attempt has been made to increase the solubility of these 
tricyclic compounds. It can be achieved by replacing the oxygen atom at position 2 of pyrone 
with a nitrogen atom. This was achieved by heating 4-hydroxy-6-methyl-2-pyrone (24) and p-
methoxy benzyl amine MPM (54) in water for 24h followed by filtration of desired compound 
55 in 60% yield.80 We suspect the attack of amine group to MPM to the pyrone and leads to ring 
opening followed by dehydration to form a MPM-protected pyridinone.  Compound 55 was 
treated with perialdehyde (25) in the presence of piperidine and glacial acetic acid and refluxed 
overnight in chloroform to give 56 in a 90% yield as a single diastereomer.85 The proposed 
mechanism is shown in Scheme 1.12. Selective hydroxylation of 56 was achieved by 
hydroboration followed by oxidation to furnish compound 57 in a 69% yield. The mesylated 
product 58 was obtained by treating the alcohol with triethylamine and methanesulfonyl 
chloride. Displacement of methanesulfonyl functional group with adenine was achieved by 
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heating the reaction mixture in DMA at 150°C. Compound 59 was purified by column 
chromatography. The N3’-regiochemistry is similar to that of CP2 (2) and is unequivocally 
assigned by 2D NOESY NMR spectroscopy (Scheme 1.12). The final step involved the removal 
of the MPM group but was unsuccessful with DDQ, CAN, and TFA as either no reaction or 
decomposition of the starting material was observed. An alternate approach was therefore 
employed (Scheme 1.12).75 
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Scheme 1.12. Synthesis of a novel protected N2’ pyridinone compound. 
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Scheme 1.13. Proposed mechanism for the synthesis of tricyclic pyrone molecule 56. 
  
4-hydroxy-6-methyl-2-pyrone (24) was heated in the presence of a 28% NH4OH solution 
for 6 h, resulting in the formation of yellow precipitate, which was filtered and crystallized from 
ethanol to afford 61 in an 80% yield as a yellow solid.86 A mixture of pyridinone (61), 
perialdehyde (25), piperidine and glacial acetic acid was refluxed overnight in chloroform to 
yield 62 in a 91% yield.85 Protection of the pyridinone nitrogen was achieved by its treatment 
with triethylamine base followed by addition of di-tert-butyldicarbonate (Boc)2O at 0°C 
overnight to afford 63 in 97% yield. Selective hydroxylation of the terminal double bond was 
obtained by treating 63 with BH3•THF in THF at –20°C followed by oxidation with H2O2 and 
NaOH, which resulted in the formation of compound 64 in 65% yield as two diasteromers in 1:1 
ratio. Mesylated product 65 was obtained by treating the alcohol with triethylamine and 
methanesulfonyl chloride in a 79% yield. Displacement of the mesyl functional group with 
adenine was achieved by heating the reaction mixture in distilled DMA at 150°C for 8 h. 
Compounds 66 and 67 were purified by column chromatography. Because of high reaction 
temperature, the Boc protecting group was removed during the course of the reaction (Scheme 
1.14). The N3 and N9 regiochemistry of 66 and 67 was unequivocally assigned using 2D 
NOESY spectroscopy and was in agreement with compound 2 and 29. 
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Scheme 1.14. Synthesis of novel pyridinone compounds. 
 
The nitrogen atom at position 2 was successfully installed using ammonium hydroxide. 
The condensation reaction was used for the synthesis of tricyclic pyridinone core structure and a 
single diasteromer was obtained. The stereochemistry at C5a carbon was unambiguously 
determined through the X-ray crystallography analysis.  
 
1.3.6. Synthesis of bicyclic pyrone and pyridinones analogs 
 
More recently, we focused our attention on the synthesis of an array of bicyclic 
compounds with different substituents attached to them and in the screening of their anti-AD 
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activity. Pyridinone 61 was treated with triethylorthoformate and aniline in DMF:Acetic acid 
(3:1) mixture and refluxed for two hours. After the aqueous work up, 68 was obtained in 72% 
yield.87 Aldehyde 69 was obtained from 68 by refluxing it in 5% aqueous potassium carbonate 
solution for one hour in an open reaction vessel.88 Ethanol was used as a crystallization solvent 
to obtain aldehyde product in 95% yield as yellow solid. Treatment of 69 with 
[(methoxycarbonyl)methylene]triphenyl phosphorane in refluxing toluene for 2 hours led to the 
formation of 3,4-unsubstituted pyranopyridine 70 in 60% yield (Scheme 1.15).89 
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Scheme 1.15. Synthesis of novel bicyclic pyridinone compounds using a Wittig reagent. 
 
1.4 Conclusion and future work 
 
Neurodegenerative diseases mainly occur because of protein misfolding. There is no cure 
for AD. In our laboratory, we are currently synthesizing different tricyclic pyrones and 
pyridinones, modifying L-shape fused pyranoisoquinolinone, and synthesized tricyclic 
pyridinones containing a nitrogen atom at 2 position as well as analogs having a nitrogen atom at 
position 5. CP2 has a structural scaffold that is accessible for optimization and for further 
synthesization for more CP2 analogs by modification at positions C11 and C13. These 
potentially position modifications remains a part of our future work. 
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1.5 Experimental Section  
 
(5aS,7S)-7-Isopropenyl-3-methyl-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1] 
benzopyran (24) 
 
O
O
O
H
 
 
To a solution of 5 g (0.04 mol) of 24 in 200 ml of ethyl acetate under argon at room 
temperature was added 6.55 g (0.04 mol) of aldehyde 25 and 2.28 g (0.02 mol) of L-proline. The 
reaction mixture was heated to reflux for 5 h. The progress of the reaction was monitored using 
TLC using hexane and ethyl acetate as a developing solvent. The reaction mixture was washed 
with water and brine. The organic layer was extracted with ethyl acetate. The organic layer was 
dried with anhydrous sodium sulfate, filtered and concentrated. Column chromatographic on 
silica gel using gradient mixture of hexane and ethyl acetate afforded to give a yellow solid of 26 
in 78% yield. Purification can also be performed by recrystallization using ethyl acetate as a 
solvent. [α]22D = +31.90 (c 0.75, CHCl3); 1H NMR (CDCl3) δ 6.1 (s, 1H, C10H), 5.72 (s, 1H, 
C4H), 5.1 (dd, J = 11 Hz, 5Hz, 1H, C5a H), 4.75 (m, 1H, =CH), 4.73 (m, 1H, =CH), 2.48 (ddd, 
J=14Hz, 4Hz, 2.4Hz, 1H), 2.22-2.02 (m, 3H), 2.19 (s, 3H, C4-Me), 1.88-1.72 (m, 2H), 1.74(s, 
3H, MeC=), 1.31 (ddd, J = 25Hz, 12.8Hz, 4Hz, 1H); 13C NMR δ 163.4, 162.6, 161.7, 147.9, 
132.3, 109.8, 109.6, 99.9, 97.5, 79.4, 43.6, 40.0, 32.5, 32.1, 20.9, 20.3.; MS FAB, m/z 259 (M + 
1). 
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(5aS,7S)-7-[(1R) and (1S)-2-Hydroxy-1-methylethyl]- 3-methyl-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (27) 
 
O
O
O
H
OH  
To a cold solution (-20ºC) of 3 g (11.74 mmol) of 26 in 25 mL of THF under argon, was 
added 5.85 mL  (5.85 mmol) of BH3·THF complex (1.0 M in THF).  After stirring the solution at 
-20ºC for 1 h, kept in the refrigerator for 48 h at -20ºC. Warm to 0ºC and added 15 mL of 0.5% 
aqueous NaOH and 8 mL of 30% hydrogen peroxide were added. The solution was stirred for 2 
h, diluted with 200 mL of water, and extracted three times with dichloromethane. The combined 
organic layer was washed with 100 mL of brine, dried (MgSO4), concentrated, and column 
chromatographed on silica  gel  using  a  gradient  mixture  of  hexane  and  diethyl ether as 
eluents to give 1.72 g (63% yield; based on reacted 26) of 27 as a mixture of two diastereomers 
at C12 (1:1; based on 13C NMR spectrum) and 0.43 g (14% recovery) of 27. 1H NMR (CDCl3) δ 
6.08  (s, 1H, C4H), 5.71  (s, 1H, C10H), 5.07  (t, J= 5.2 Hz, 1H, C5aH), 3.62 – 3.52 (m, 2H, 
CH2O), 2.46 (m,1H), 2.19 (s, 3H, Me), 2.13 – 1.99 (m, 2H), 1.73 – 1.51 (m, 3H),  1.19 – 1.12  
(m, 2H),  0.92  (d,  J=7 Hz,  3H,  Me);  13C NMR  (two  diastereomers) δ 163.5,  162.8,  161.6,  
133.0, 109.0, 100.0, 97.4, 79.7, 79.6, 65.6, 39.9, 39.8, 39.4, 37.2, 37.1, 36.9, 32.4, 32.3, 31.1, 
30.4, 28.5, 20.1, 13.2 (Me for a diastereomer),  13.1  (Me  for  another  diastereomer). 
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(5aS,7S)-3-Methyl-7-[(1R) and (1S)- 2-(methanesulfonyloxy)-1-methylethyl]-1H,7H-
5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (28) 
 
O
O
O
H
OMs  
To a cold (0ºC) solution of 1.72 g (6.23 mmol) of 27 in 20 mL of methylene chloride 
under argon, were added 2.62 mL (18.69 mmol) of triethylamine and 0.72 mL (9.35 mmol) of 
dimethylacetamide chloride.  The solution was stirred for 3h, diluted with 50 mL of NaHCO3, 
and extracted three times with methylene chloride. The combined dichloromethane layer was 
washed with washed with brine, dried (MgSO4), concentrated, and column chromatographed on 
silica gel using a gradient mixture of hexane and ether as eluents to give 2.16g (94% yield) of   
28 as   a   mixture   of   two diastereomers  (1:1; based on 13C NMR spectrum).  1H NMR δ 6.08 
(s, 1H, C4H), 5.71 (s, 1H, C10H), 5.06 (m, 1H, CHO), 4.18 – 4.08 (m, 2H, CH2O), 3.03 (s, 3H, 
MeS), 2.49 (d, J=2.8 Hz, 1H), 2.19  (s, 3H, Me), 2.14 – 1.11  (m, 7H), 0.98  (d, J=6.8 Hz, 3H, 
Me); 13C  NMR δ 163.2,  162.4, 161.7, 132.1, 109.6, 105.2, 99.8, 79.2, 79.1, 72.3, 38.9, 37.5, 
37.4, 37.3, 37.2, 36.9, 32.2, 32.1, 30.8, 28.6, 20.2, 13.3 (Me for  a  diastereomer),  13.2  (Me  for  
another  diastereomer).  
 
(5aS,7S)-7-[(1R) and (1S)-2-Bromo-1-methylethyl]- 3-methyl-1H,7H-5a,6,8,9-tetrahydro-1-
oxopyrano[4,3-b][1]benzopyran (39) 
 
O
O
O
H
Br  
To a cold (0ºC) solution of 0.50 g (1.83 mmol) of 27 (2 diastereomers at C12) and 0.96 g 
(3.65 mmol) of triphenyl phosphine in 10 mL of dichloromethane under argon was added 1.52 g 
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(4.56 mmol) of carbon tetrabromide in small portions.  The reaction was stirred at 0ºC for one 
hour.  The solvent was removed using a rotary evaporator and the residue was subjected to a 
silica gel column (the silica gel was pre-treated with 1% triethylamine before packing the 
column) using a gradient mixture of hexane and diethyl ether as eluents to give 0.56 g (91% 
yield) of 39.  1H NMR δ 6.09 (s, 1 H), 5.71 (s, 1 H), 5.08 (dt, J = 12, 7 Hz, 1 H, C5aH), 3.41 (d, J 
= 4 Hz, 2 H, CH2Br), 2.47 (dd, J = 14, 4 Hz, 1 H), 2.19 (s, 3 H, Me), 2.18 – 2.10 (m, 1 H), 2.03 
(q, J = 11 Hz, 1 H), 1.80-1.70 (m, 3 H), 1.60 – 1.50 (m, 1 H), 1.20 – 1.16 (m, 1 H), 1.03 (d, J = 7 
Hz, 3 H, Me); 13C NMR δ (2 diasteromers) 163.4, 162.6, 161.8, 132.4, 109.5, 99.9, 97.5, 79.4, 
79.3, 39.6, 39.5, 39.2, 39.1, 38.8, 38.7, 37.0, 32.2, 32.1, 31.0, 28.7, 20.3, 15.9, 15.8.  HRMS 
calcd for C16H20BrO3 (M+H+) 339.0596, found 339.0597.  
 
(5aS,7S)-7-[(1R) and (1S)- 2-(N3-adenyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetra hydro-1-oxopyrano[4,3-b][1]benzopyran (2) 
O
O
O
H
N
N N
N
NH2
 
 
(5aS,7S)-7-[(1R) and (1S)-2-(N9-Adenyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-tetra 
hydro-1-oxopyrano[4,3-b][1]benzopyran (29) 
 
O
O
O
H
N
NN
N
NH2
 
 
In a round bottom flask fitted with reflux condenser, taken 1.0 g of mesylate 28 (2.7 
mmol) and 0.36 g of adenine (2.7 mmol) together and vacuum dried, purge argon and added 8 
mL of DMA (dried over CaH2) and reflux at 140°C overnight. TLC showed no starting material. 
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Cool to RT, dilute sodium bicarbonate and extract twice with methylene chloride and with 5% 
methanol in methylene chloride. Combined organic layer washed with brine, dried over sodium 
sulfate and column chromatographed on silica using methylene chloride and methanol as eluent 
to afford CP2 (2) in 21% yield and TP2 (29) in 6% yield. Compound 29 (less polar; two 
diastereomers at C12); 1H NMR δ 8.36 (s, 1H, C2’H), 7.78 (s, 1H, C8’H), 6.09 (s, 1H, C4H), 
5.89 (bs, 2H, NH2, 5.72 (s, 1H, C10H), 5.01 (m, 1H, C5aH), 4.24 (dd, J= 14, 7 Hz, 1H, CHN), 
4.01 (dd, J = 14, 7 Hz, 1H, CHN), 2.5–1.2 (a serious of m, 8H), 2.19 (s, 3H, Me), 0.90 (d, J = 7 
Hz, 3H, Me); 13C NMR δ 163.4, 162.7, 161.9, 155.6 (adenine moiety), 153.5 (adenine moiety), 
150.6 (adenine moiety), 140.9 (adenine moiety), 132.1, 119.8 (adenine moiety), 109.9, 99.9, 
97.5, 79.4, 79.2, 47.9, 39.3, 38.4, 38.3, 38.1, 38.0, 36.2, 32.3, 32.1, 31.1, 27.8, 20.3, 13.8. 
Compound 2 (more polar; 2 diastereomers at C12); 1H NMR δ 8.07 (s, C8 H of adenine), 7.98 
and 7.97 (2 s, 1H, C2H of adenine; 2 diastereomers), 6.10 (s, 1H, C10H), 5.72 and 5.71 (2s, 1H, 
C4H), 5.02 (m, 1H, C5aH), 4.50 (dd, J = 14, 7 Hz, 1H, CHN), 4.08 (2dd, J =14, 8 Hz, 1H, CHN; 
2 diastereomers), 2.46 (m, 2H), 2.20 and 2.19 (2s, 3H, Me; 2 diastereomers), 2.10–1.22 (a series 
of m, 6H), 0.91 (d, J1/47.0 Hz, 3H, Me). 13C NMR (2 diastereomers) δ 163.2 and 163.1, 162.4, 
161.7, 154.4,154.0, 150.7, 142.3, 131.7 and 131.6, 121.0, 199.8, 99.7, 97.3, 79.0, 78.8, 54.5 and 
54.4, 38.9, 38.1 and 38.0, 37.1 and 36.9, 36.1, 32.0 and 31.9, 30.7, 27.6, 20.1, 13.3 and 13.2. 
HRMS calculated for C21H24N5O3 (M+H) 394.1881, found 394.1875. 
 
((2-hydroxyethyl)-7-isopropenyl-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3b][1]benzo 
pyran (30) 
O
O
O
H
OH
 
 
To a solution of 0.4 mL of diisopropylamine in 28 mL of THF was cooled to –20°C. To 
this solution 1.8 mL of 1.6M nBuLi was added and stirred for 30 minutes. Thus obtained 
solution is the freshly prepared LDA and the reaction vessel is maintained at –20°C to reduce the 
decomposition. In another flask, to a solution of 250 mg (0.969 mmol) of 26 in 5 mL THF was 
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cooled to –78°C. To this solution 19.4 mL (1.9372 mmol) of freshly prepared LDA was added 
via syringe. After five minutes of stirring at –78°C the solution turned deep blue in color 
indicating the formation of anion. This solution was stirred at –78°C for 2 h. In another flask a 
suspended solution of 290 mg (9.6899 mmol) of paraformaldehyde in 10 mL THF was taken and 
cooled to 0°C. The anion formed in another flask is transferred to the paraformaldehyde-THF 
mixture via cannula and allowed to stir at 0°C and slowly warmed to room temperature. The 
color of the solution turned reddish brown after reaching to room temperature. The progress of 
the reaction was monitored using TLC using hexane and diethylether as a developing solvent. 
The reaction mixture was washed with water and extracted using methylene chloride. The 
organic layer was washed with aqueous sodium bicarbonate solution and brine, dried over 
anhydrous sodium sulfate, filtered and concentrated. Column chromatographic on silica gel using 
gradient mixture of hexane and diethyl ether afforded to give a moderate yield 28% of 30 and 
15% of starting material 26. [α]D23 = +23.7o (C 3.5, CHCl3); 1H NMR CDCl3 δ 6.06 (s, 1 H), 
5.86 (s, 1 H), 5.11 (dd, J = 11, 4.4 Hz, 1 H, C5a-H), 4.75 (s, 1 H, =CH2), 4.73 (s, 1 H, =CH2), 
3.90 (t, J = 6.2 Hz, 2 H, CH2O), 2.69 (t, J = 6.2 Hz, CH2), 2.48 (m, 1 H), 2.20 ~ 1.70 (a series of 
m, 5 H), 1.73 (s, 3 H, Me), 1.34 ~ 1.25 (m, 1 H); 13C NMR δ 163.3, 162.1, 148.0, 132.8, 109.9, 
109.1, 101.1, 98.2, 79.6, 59.6, 43.6, 40.0, 37.3, 32.6, 32.1, 30.5, 20.9. HRMS calculated for 
C17H21O4 (M+H) 289.1440, found 289.1411. 
 
(5aS,7S)-3-(2-Acetoxyethyl)-7-isopropenyl-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3b][1] 
benzopyran (31) 
O
O
O
H
OAc
 
 
To a solution of 202 mg (0.7014 mmol) of 30 in 3 mL of distilled pyridine was added 143 
mg (1.402 mmol) of acetic anhydride at 0°C. The reaction mixture was stirred at 0°C for 7 h. The 
progress of the reaction was monitored using TLC using hexane and diethylether as a developing 
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solvent. The reaction mixture was washed with water and extracted with ethyl acetate. The 
organic layer was washed with 1M HCl, aqueous sodium bicarbonate and brine, dried over 
anhydrous sodium sulfate, filtered and concentrated. Column chromatographic on silica gel using 
gradient mixture of hexane and diethyl ether afforded to give 140 mg of 31 in 62% yield. [α]D23 
= +16.9o (C 0.15, CHCl3); 1H NMR CDCl3 δ 6.10 (s, 1 H), 5.79 (s, 1 H), 5.13 (dd, J = 11.2, 4.8 
Hz, 1 H, C5a-H), 4.75 (s, 1 H, =CH2), 4.73 (s, 1 H, =CH2), 4.33 (t, J = 6.4 Hz, 2 H, CH2O), 2.76 
(t, J = 6.4 Hz, CH2), 2.48 (m, 1 H), 2.20 ~ 1.70 (a series of m, 5 H), 1.74 (s, 3 H, Me), 1.28 (qd, J 
= 12.8, 4 Hz, 1 H); 13C NMR δ  170.9, 163.0, 160.9, 147.9, 132.9, 110.0, 109.6, 100.8, 98.5, 
79.6, 60.8, 43.6, 40.0, 33.6, 32.5, 32.1, 30.5, 20.1, 20.9. HRMS calculated for C19H23O5 (M+H) 
331.1545, found 331.1536. 
 
(5aS,7S)-3-(2-Acetoxyethyl)-7-(2-hydroxy-1-methylethyl)-1H,7H-5a,6,8,9-tetrahydro-1-
oxopyrano[4,3-b][1]benzopyran (32) 
 
O
O
O
H
OAc
OH  
To a solution of 143 mg (0.433 mmol) of 31 in 3 mL THF under argon was added 0.43 
mL (0.433 mmol) of 1M BH3•THF and the solution was stirred at -78°C for 30 minutes and 
stirred at -20°C for two days. To the solution at 0°C, 1 mL of water, 0.5 mL of 0.1% NaOH 
aqueous solution, and 0.5 mL of 30% H2O2 were added, and the resulting solution was stirred for 
1 h. The solution was washed with water and extracted with methylene chloride. The organic 
layer was washed with aqueous solution of ammonium chloride and brine, dried over anhydrous 
sodium sulfate, filtered and concentrated. Column chromatographic on silica gel using gradient 
mixture of hexane and diethyl ether afforded to give 72 mg of 32 in 56% yield along with 14% 
recovery of starting material 31. 1H NMR CDCl3 δ 6.07 (s, 1 H), 5.78 (s, 1 H), 5.10 (m, 1 H, 
C5a-H), 4.32 (t, J = 6.2 Hz, 2 H, CH2O), 3.56 (m, 2 H, CH2OH) 2.76 (t, J = 6.2 Hz, CH2), 2.47 
(m, 1 H), 2.17 ~ 1.10 (a series of m, 7 H), 0.91 (d, J = 7 Hz, 1 H); 13C NMR δ 170.9, 163.0, 
  36 
160.9, 133.4, 118.1, 109.3, 100.8, 98.5, 79.9, 66.0, 60.8, 40.2, 39.5, 37.6, 37.5, 37.3, 33.6, 31.2, 
21.0. HRMS calculated for C19H25O6 (M+H) 349.1651, found 349.1649. 
 
(5aS,7S)-3-(2-Acetoxyethyl)-7-[(2-methanesulfonyloxy)-1-methylethyl]-1H,7H-5a,6,8,9- 
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (33) 
 
O
O
O
H
OAc
OMs  
To a solution of 85 mg (0.2442 mmol) of 32 in 3 mL of methylene chloride was added 
0.11 mL (0.7326 mmol) of triethylamine at 0°C. To the above solution 28 µL (0.3664 mmol) of 
methanesulfonyl chloride was added at 0°C, the resulting mixture was stirred at room 
temperature for 3 h. The progress of the reaction was monitored using TLC using hexane and 
diethyl ether as a developing solvent. The reaction mixture was washed with water and extracted 
with methylene chloride. The organic layer was washed with aqueous solution of sodium 
bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column 
chromatographic on silica gel using gradient mixture of hexane and diethyl ether afforded to give 
94 mg of 33 in 90% yield. 1H NMR CDCl3 δ 6.05 (s, 1 H), 5.76 (s, 1 H), 5.07 (m, 1 H, C5a-H), 
4.29 (t, J = 6.3 Hz, 2 H, CH2O), 4.10 (m, 2 H, CH2OS), 3.00 (s, 3 H, CH3S), 2.73 (t, J = 6.3 Hz, 
CH2), 2.47 (d, J = 14 Hz, 1 H), 2.17 ~ 1.10 (a series of m, 7 H), 2.02 (s, 3 H, CH3CO), 0.96 (d, J 
= 7 Hz, 1 H); 13C NMR δ 170.9, 162.9, 162.3, 161.1, 132.7, 109.7, 100.7, 98.4, 79.4, 72.3, 60.8, 
39.1, 37.6, 37.5, 37.4, 33.6, 32.3, 30.9, 13.3. HRMS calculated for C20H27O8S (M+H) 427.1426, 
found 427.1434. 
 
(5aS,7S)-3-(2-Acetoxyethyl)-7-[(1R) and (1S)- 2-(N3-adenyl)-1-methylethyl]-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (34) 
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To a solution of 94 mg (0.22 mmol) of 33 in 1.5 ml of DMA was added 33 mg (0.2442 
mmol) of adenine and the resulting mixture was heated to 150°C for 7 h. The reaction mixture 
was cooled to room temperature and 50 mg (0.59 mmol) of sodium bicarbonate was added and 
DMA was distilled out under reduced pressure to obtain a brown residue. This residue was made 
to dissolve in minimum amount of methanol and applied to column directly. Column 
chromatographic on silica gel using gradient mixture of chloroform and methanol afforded to 
give 5 mg of 34 in low yields. The product was further purified by HPLC using acetonitrile, 
water and 0.1% trifluoro acetic acid as solvents to give pure 34. 1H NMR CDCl3 δ 8.07 (s, C8’H 
of adenine), 8.01 & 8.00 (2s, 1 H, C2’H of adenine; 2 diastereomers), 6.10 (s, 1 H, C10H), 5.79 
& 5.78 (2s, 1 H, C4H), 5.05 (m, 1 H, C5aH), 4.54 (2dd, J = 13.5, 6.5 Hz, 1 H, CHN; 2 
diastereomers), 4.34 & 4.33 (2t, J = 6.2 Hz, 2 H, CH2O; 2 diastereomers), 4.07 (dd, J = 13.5, 8 
Hz, 1 H, CHN), 2.78 & 2.76 (2t, J = 6.2 Hz, 2 H, CH2; 2 diastereomers), 2.07 & 2.06 (2s, 3 H, 
Me; 2 diastereomers), 2.60 ~ 1.22 (a series of m, 8 H), 0.91 (d, J = 7.0 Hz, 3 H, Me). 13C NMR  
182.0, 181.6, 164.8, 163.3, 161.1, 155.8, 152.9, 148.0, 141.6, 131.1, 129.6, 129.1, 121.3, 100.7, 
79.1, 78.9, 63.8, 59.2, 50.5, 33.6, 29.9, 21.1, 15.1. HRMS calculated for C24H28N5O5 (M+H) 
466.2090, found 466.2081. 
 
(5aS,7S)-7-[(3-acetoxy-1-propen-2-yl)]-3-methyl-1H,7H-5a,6,8,9-tetrahyro-1-oxopyranol 
[4,3-b][1]benzopyran (35) 
O
O
O
H
O
O  
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A solution of 200 mg (0.78 mmol) of 26, 17 mg (78 µmol) of palladium acetate, 0.25 g 
(2.3 mmol) of benzoquinone, and 25 mg (0.16 mmol) of diethyl malonate in 5 mL of acetic acid 
under argon was stirred and heated to 75°C for 2 h and 47°C for 24 h.  The reaction solution was 
cooled to 25°C, filtered through celite, washed with aqueous NaHCO3, water, and brine, dried 
(anhydrous Na2SO4), concentrated and column chromatographed on silica gel using a mixture of 
hexane: ethyl acetate as eluent to give 0.15 g (60% yield) of 35 (5aS, 7S)-7-[(3-acetoxy-1-
propen-2-yl)]-3-methyl-1H, 7H-5a,6,8,9-tetrahyro-1-oxopyranol[4,3-b][1]benzopyran.  [α]22D = 
+24.3° (c 0.07, CHCl3);  1H NMR δ 6.12 (s, 1 H), 5.73 (s, 1 H), 5.12 (s, 1 H, =CH2), 5.10 - 5.09 
(m, 1 H, CHO), 5.02 (s, 1 H, =CH2), 4.58 (s, 2 H, CH2OAc), 2.51 (dt, J = 14, 4 Hz, 1 H), 2.28 - 
2.24 (m, 2 H), 2.20 (s, 3 H, Me), 2.11 (s, 3 H, CH3CO), 2.11 ~ 2.05 (m, 1 H), 1.93 – 1.89 (m, 1 
H), 1.77 (dd, J = 12, 11 Hz, 1 H), 1.36 – 1.31 (m, 1 H); 13C NMR δ 170.9, 163.4, 162.7, 161.9, 
146.4, 131.8, 112.9, 110.0, 99.9, 97.5, 79.2, 66.1, 40.0, 39.5, 32.4, 32.3, 21.2, 20.3.  HRMS 
calculated for C18H21O5 (M+H+) 317.1389, found 317.1396. 
 
(5aS,7S)-7-[(3-Hydroxy-1-propen-2-yl)]-3-methyl-1H,7H-5a,6,8,9-tetrahyro-1-oxopyrano 
[4,3-b][1]benzopyran (36) 
 
O
O
O
H
OH  
 
A solution of 0.59 g (1.9 mmol) of the above acetoxy tricyclic pyrone 35 and 0.51 g (3.7 
mmol) of potassium carbonate in 5 mL of methanol was stirred at 0°C for 1 h.  The solution was 
neutralized with 1 N HCl, and extracted with dichloromethane three times.  The combined 
extract was washed with aqueous NH4OH, water, and brine, dried (MgSO4), concentrated, and 
column chromatographed on silica gel using a gradient mixture of hexane and ether as eluents to 
give 0.42 g (82% yield) of compound 36. [α]22D = +20.0o (c 0.05, CHCl3); 1H NMR δ 6.12 (s, 1 
H), 5.73 (s, 1 H), 5.13 – 5.12 (m, 1 H, CHO), 5.11 (s, 1 H, =CH2), 4.94 (s, 1 H, =CH2), 4.15 (d, J 
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= 7 Hz, 2 H, CH2O), 2.51 (dt, J = 14, 4 Hz, 1 H), 2.34 - 2.23 (m, 2 H), 2.20 (s, 3 H, Me), 2.18 ~ 
2.08 (m, 1 H), 1.93 – 1.83 (m, 1 H), 1.77 (q, J = 12 Hz, 1 H), 1.40 – 1.28 (m, 1 H); 13C NMR δ 
163.5, 162.7, 161.7, 151.4, 132.2, 109.5, 109.4, 99.9, 97.4, 79.3, 64.9, 40.2, 38.9, 32.4 (2 C), 
20.2; HRMS calculated for C16H19O4 (M+H+) 275.1283, found 275.1305. 
 
(5aS,7S)-7-[(3-methanesulfonyloxy-1-propen-2-yl)]-3-methyl-1H,7H-5a,6,8,9-tetrahyro-1-
oxopyranol[4,3-b][1]benzopyran (37) 
O
O
O
H
OMs  
A cold (0°C) solution of 0.15 g (0.54 mmol) of alcohol 36, 92 mg (0.80 mmol) of 
methanesulfonyl chloride, 0.20 mL (1.61 mmol) of triethylamine in 5 mL of methylene chloride 
was stirred under argon for 2 h.  The reaction solution was diluted with dichloromethane (30 mL) 
and washed with aqueous NaHCO3, water, and brine, dried (anhydrous Na2SO4), concentrated, 
column chromatographed on silica gel using a gradient mixture of hexane, diethyl ether and ethyl 
acetate as eluents to give 77 mg (41% yield) of 37. [α]22D = +21.1o (c 0.09, CHCl3); 1H NMR δ 
6.10 (s, 1 H), 5.71 (s, 1 H), 5.26 (s, 1 H, =CH2), 5.14 (s, 1 H, =CH2), 5.11 (dd, J = 12, 5 Hz, 1 H, 
CHO), 4.70 (s, 2 H, CH2O), 3.03 (s, 3 H, SCH3), 2.51 (dt, J = 14, 3 Hz, 1 H), 2.37 - 2.20 (m, 2 
H), 2.19 (s, 3 H, Me), 2.15 ~ 2.03 (m, 1 H), 1.95 – 1.89 (m, 1 H), 1.77 (dd, J = 12, 11 Hz, 1 H), 
1.32 (qd, J = 13, 4 Hz, 1 H); 13C NMR δ 163.4, 162.6, 161.9, 144.8, 131.5, 116.1, 110.1, 99.9, 
97.5, 78.9, 71.5, 39.8, 38.7, 38.1, 32.2, 32.1, 20.3; HRMS calculated for C17H21O6S (M+H+) 
353.1059, found 353.1044. 
 
(5aS,7S)-7-{[3-(6-Amino-9H-purin-3-yl)-1-propen-2-yl]}-3-methyl-1H,7H-5a,6,8,9- 
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (38) 
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A solution of 77 mg (0.22 mmol) of mesylate 37 and 30 mg (0.22 mmol) of adenine in 
1.5 mL of DMA was heated at 150°C under argon for 10 h.  DMA was removed via distillation 
under vacuum (0.1 mm Hg), and the residue was subjected to silica gel column chromatography 
using a gradient mixture of hexane, ethyl acetate, and methanol as eluents to give 19 mg (26% 
yield) of compound 38.  [α]22D = -24.7° (c 0.09, CHCl3) 1H NMR δ 8.07 (s, 1 H, C2’H), 8.02 (s, 
1 H, C8’H), 6.11 (s, 1 H), 5.72 (s, 1 H), 5.14 (s, 1 H, CH2N), 5.05 (s, 2 H, =CH2), 5.03 – 5.00 (m, 
1 H, CHO), 4.92 (s, 1 H, CH2N), 2.50 – 2.42 (m, 1 H), 2.32 - 2.29 (m, 1 H), 2.26 – 2.12 (m, 1 H), 
2.20 (s, 3 H, Me), 2.08 ~ 1.93 (m, 2 H), 1.80 (q, J = 12 Hz, 1 H), 1.36 (qd, J = 12, 4 Hz, 1 H); 
13C NMR δ 163.4, 162.6, 162.0, 154.5, 154.2, 151.1, 145.9, 142.6, 131.3, 120.8, 114.2, 110.2, 
99.9, 97.5, 78.8, 53.1, 39.9, 39.5, 32.3, 32.2, 20.3; HRMS calculated for C21H22N5O3 (M+H+) 
392.1723, found 392.1715. 
 
(5aS,7S)-7-[(1R) and (1S)-2-(6-chloropurin-9-yl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (40) 
 
O
O
O
H
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To a solution of 3.0 mg (0.15 mmol) of NaH in 1.5 mL of DMF under argon was added 
23 mg (0.15 mmol) of 6-chloropurine at 25°C, and the solution was stirred for 1 h.  This solution 
was then added to a solution of 50 mg (0.15 mmol) of bromide 39 in 1.5 mL of DMF via 
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cannula.  The reaction solution was stirred at 25°C for 24 h and 80°C for 20 h, diluted with 
aqueous NH4Cl, and extracted twice with diethyl ether.  The combined organic layer was washed 
with brine, dried (MgSO4), concentrated and column chromatographed on silica gel using a 
gradient mixture of dichloromethane and methanol as eluents to give 50 mg (82% yield) of 
compound 40 (as two diastereomers at C12). 1H NMR δ 8.69 & 8.68 (2 s, 1 H, C2’H), 8.04 & 
8.03 (2 s, 1 H, C8’H), 6.03 (s, 1 H), 5.66 & 5.64 (2 s, 1 H), 5.00 – 4.90 (m, 1 H, C5aH), 4.28 
(ddd, J = 14, 7, 2 Hz, 1 H, CH2N), 4.04 (ddd, J = 14, 9, 3 Hz, 1 H, CH2N), 2.48 – 2.38 (m, 1 H), 
2.13 & 2.12 (2 s, 3 H, Me), 2.20 - 2.02 (m, 2 H), 1.96-1.78 (m, 1 H), 1.79 – 1.56 (m, 1 H), 1.50 – 
1.40 (m, 1 H), 1.34 - 1.18 (m, 2 H), 0.91 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 163.4 & 163.3, 
162.7 & 162.6, 161.9, 152.2, 151.4, 145.5, 131.8, 110.0, 99.8, 97.5, 79.2 & 79.0, 48.4 & 48.3, 
39.1, 38.4 & 38.3, 38.26 & 38.2, 36.6, 36.4, 32.2 & 32.0, 31.6, 30.9, 28.0, 20.3, 13.94 & 13.91.  
HRMS calculated for C21H22ClN4O3 (M+H+) 413.1380, found 413.1372. 2D NOESY spectrum 
shows correlation of δ C8’-H (δ7.21 ppm) signal with CH2N (δ 3.93 and 3.39 ppm) peaks. 
 
(5aS,7S)-7-[(1R) and (1S)-2-(N1-cytosinyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9 
tetrahyro-1-oxopyrano[4,3-b][1]benzopyran (41) 
O
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(5aS,7S)-7-((R)-1-(4-amino-1,2-dihydropyrimidin-2-yloxy)propan-2-yl)-6,7,8,9-tetrahydro-
3-methylpyrano[4,3-b]chromen-1(5aH)-one (42) 
 
O
O
O
H
HN
NO
NH2
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To a solution of 24 mg (0.59 mmol) of NaH in 3 mL of DMF under argon was added 66 
mg (0.59 mmol) of cytosine at 25°C, and the solution was stirred for 1 h.  This solution was then 
added to a solution of 0.20 g (0.59 mmol) of bromide 39 in 2 mL of DMF via cannula, and the 
resulting solution was stirred at 25°C for 24 h and 85°C for 24 h.  The reaction solution was 
diluted with dichloromethane and washed with water, and brine, dried (anhydrous Na2SO4), 
concentrated, and column chromatographed on silica gel using a gradient mixture of 
dichloromethane and methanol as eluents to give 21 mg (10% yield) of compound 42 (less polar; 
2 diastereomers (-O compound) and 62 mg (28% yield) of compound 41 (more polar; 2 
diastereomers) along with 25 mg of tricyclic pyrone 26 (from dehydrobromination reaction).  
Compound 41: (more polar) 1H NMR δ 7.21 (d, J = 7 Hz, 1 H, C6’H), 6.04 (s, 1 H), 5.87 (d, J = 
7 Hz, 1 H, C5’H), 5.72 (s, 1 H), 5.06 – 5.00 (m, 1 H, C5aH), 3.98 – 3.84 (m, 1 H, CH2N), 3.42 – 
3.33 (m, 1 H, CH2N), 2.48 – 2.38 (m, 1 H), 2.30 – 2.10 (m, 1 H), 2.19 (s, 3 H), 2.08 – 1.92 (m, 2 
H), 1.78 – 1.52 (m, 3 H0, 1.30 – 1.12 (m, 1 H), 0.84 (d, J = 6 Hz, 3 H); 13C NMR δ 165.5, 163.6, 
162.7, 161.9, 156.9, 146.0, 132.5, 109.4, 100.0, 97.4, 95.2, 79.46 & 79.40, 53.9, 38.3, 37.1 & 
36.5, 32.3, 31.8 & 31.0, 29.9 & 28.0, 20.3, 13.5.  2D NOESY spectrum shows correlation of δ 
7.21ppm signal with δ 3.93 and 3.39 ppm. Compound 42 (less polar):  1H NMR δ 8.02 (d, J = 7 
Hz, 1 H, C6’H), 6.10 (d, J = 7 Hz, 1 H, C5’H), 6.07 (s, 1 H), 5.70 (s, 1 H), 5.08 (m, 1 H, C5aH), 
4.97 (s, 2 H, NH2), 4.22 - 4.13 (m, 2 H, CH2N), 2.46 (d, J = 14 Hz, 1 H), 2.19 (s, 3 H, Me), 2.15 
- 1.54 (m, 5 H), 1.34 - 1.10 (m, 2 H), 1.01 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 165.4, 164.9, 
163.5, 162.8, 161.7, 157.6, 133.0, 109.3, 100.0, 99.7, 97.5, 79.8 & 79.6, 69.7, 39.4, 37.4 & 37.3, 
37.2 & 37.1, 36.9, 32.5 & 32.4, 31.2 & 28.5, 20.3, 13.5 & 13.4.  HRMS calcd for C20H24N3O4 
(M+H+) 370.1767, found 370.1760.  2D NOESY spectrum shows no correlation between δ 8.02 
and 4.22 – 4.13 ppm. 
 
(5aS,7S)-7-[(1R) and (1S)-2-Amino-1-methylethyl)- 3-methyl-1H,7H-5a,6,8,9-tetrahydro-1-
oxopyrano[4,3-b][1]benzopyran (48) 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To a cold (-20°C) solution of 500mg (1.94 mmol) of 26 in 2 mL THF was added 0.64mL 
(0.64 mmol) of BH3•THF complex (1.0 M in THF). After stirring the solution from -20ºC to 0°C 
over a period of 30 minutes was added the hydroxylamine-O-sulfonic acid and refluxed the 
reaction mixture for 3 h. Cool down to the room temperature and diluted with 1N HCl and 
extracted with ethyl acetate twice. Combined organic layer was washed with brine, dried 
(MgSO4) and concentrated to recover 310 mg (62%) the starting material 26. The aqueous layer 
was basified using 3 M NaOH and extracted with ethyl acetate twice. Organic layer was washed 
with brine, dried (MgSO4), concentrated to give 125 mg (62%; based on reacted 26) of 48 as a 
mixture of two diastereomers at C12 (1:1; based on 13C NMR spectrum). 1H NMR δ 6.07 (s, 
1H, C4H), 5.71 (s, 1H, C10H), 5.07 (m, 1H, C5aH), 2.73 (m, 1H, 2 isomer, CHN), 2.58 (m, 1H, 
2 isomers, CHN), 2.46 (d, 1H), 2.19 (s, 3H, Me), 2.15–1.10 (m, 7H), 0.91 (d, J = 7 Hz, 3H, Me); 
13C NMR δ 163.4, 162.7, 161.7, 132.9, 109.3, 100.0, 97.5, 79.8 and 79.7 (2 isomers), 66.0, 46.0 
and 45.9 (2 isomers), 40.9, 39.1, 38.5 and 38.4 (2 isomers), 37.1, 32.6 and 32.4 (2 isomers), 31.3, 
31.2, 28.6, 20.3, 15.5, 14.3. HRMS calculated for C17H22NO3 (M+1) 276.1601, found 276.1610. 
 
(5aS,7S)-7-[(1R) and (1S)-2-(3-amino-4-cyanopyrazol-1-yl)-1-methylethyl]-3-methyl- 
1H,7H-5a,6,8,9-tetrahyro-1-oxopyrano[4,3-b][1]benzopyran (43) 
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To a mixture of 16 mg (0.15 mmol) of 3-aminopyrazole-4-carbonitrile and 6 mg (0.15 
mmol; 40% oil) of sodium hydride under argon was added 0.5 mL of DMF, and the solution was 
stirred at 25°C for 1 h.  To it was added a solution of 50 mg (0.15 mmol) of bromide 39 in 1 mL 
of DMF via cannula, and the solution was stirred at 25°C for 24 h and 85°C for 24 h.  The 
reaction solution was cooled to 25oC, diluted with dichloromethane, washed with water, and 
brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using a gradient 
mixture of hexane and ethyl acetate as eluents to give 23 mg (43% yield) 43. 1H NMR δ 7.51 and 
7.48 (2s, 1 H, C5’H), 6.10 (s, 1 H), 5.72 (s, 1 H), 5.10 – 5.00 (m, 1 H, C5aH), 4.26 (bs, 1 H, 
NH), 4.11 (bs, 1 H, NH), 3.95 (dd, J = 14, 6 Hz, 1 H, CH2N), 3.69 (dd, J = 14, 8 Hz, 1 H, 
CH2N), 2.56 – 2.42 (m, 1 H), 2.20 (s, 3 H, Me), 2.16 – 1.90 (m, 3 H), 1.80 - 1.50 (m, 3 H), 1.34 – 
1.12 (m, 1 H), 0.89 & 0.84 (2d, J = 7 Hz, 3 H, Me; 2 diastereomers); 13C NMR δ 163.5 & 163.4, 
162.8 & 162.7, 161.9, 157.0, 140.3, 134.7, 132.3 & 132.1, 114.5 & 113.8, 109.8 & 109.7, 99.9 & 
97.5, 79.4 & 79.3, 56.5 & 51.6, 39.1 & 39.06, 38.1 & 37.9, 37.5 & 37.4, 36.7 & 36.4, 32.3 & 
32.1, 28.1 & 27.9, 20.3, 13.7 & 13.6.  HRMS calculated for C20H22N4O3Na (M+Na+) 389.1590, 
found 389.1593.  2D NOESY spectrum shows correlation betweenC5’-H of pyrazole (δ 7.51 and 
7.48 ppm, two diastereomers) with 3.95 and 3.69 ppm signals. 
 
 
(5aS,7S)-7-[(1R) and (1S)-2-(pyrimidino-2-thio)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetrahyro-1-oxopyrano[4,3-b][1]benzopyran (44) 
 
O
O
O
H
N
N
S
 
 
To a mixture of 17 mg (0.15 mmol) of 2-mercaptopyrimidine and 6 mg (0.15 mmol) of 
NaH (in 40% oil) under argon was added 0.5 mL of DMF, and the solution was stirred at 25°C 
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for 1 h.  To it was added a solution of 50 mg (0.15 mmol) of bromide 39 in 1.5 mL of DMF via 
cannula, and the solution was stirred at 25°C for 48 h, diluted dichloromethane, washed with 
water, and brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using 
a gradient mixture of hexane and ethyl acetate as eluents to give 49 mg (90% yield) of compound 
44. 1H NMR δ 8.51 (d, J = 5 Hz, 1 H, C4’H), 6.97 (t, J = 5 Hz, 1 H, C5’H), 6.09 (s, 1 H), 5.71 (s, 
1 H), 5.11 – 5.02 (m, 1 H, C5aH), 3.31 (dd, J = 13, 7 Hz, 1 H, CH2S), 3.02 (dd, J = 13, 6 Hz, 1 
H, CH2S), 2.52 – 2.44 (m, 1 H), 2.20 (s, 3 H, Me), 2.08 – 1.95 (m, 1 H), 1.90 - 1.56 (m, 4 H), 
1.34 – 1.10 (m, 2 H), 1.04 (d, J = 6 Hz, 3 H, Me); 13C NMR δ 172.7, 163.4 & 163.3, 162.6, 
161.7, 157.3 (2 C), 132.7, 116.6, 109.4, 100.0, 97.5, 79.7 & 79.5, 39.9 & 39.8, 39.2, 37.5 & 37.4, 
35.6 & 35.5, 32.4 & 32.3, 31.0 & 28.5, 20.2, 16.0 & 15.9.  HRMS calculated for C20H23N2O3S 
(M+H+) 371.1429, found 371.1443. 
 
(5aS,7S)-7-[(1R) and (1S )-2-(N2-Acetyl-N9-guaninyl)-1-methylethyl]-3-methyl-1H,7H- 
5a,6,8,9-tetrahyro-1-oxopyrano[4,3-b][1]benzopyran (46) 
 
O
O
O
H
N
NHN
N N
H
O
O
 
  
To a solution of 57 mg (0.29 mmol) of N2-acetylguanine in 1 mL of DMF under argon 
was added 13 mg (40% oil; 0.32 mmol) of sodium hydride, and the solution was stirred at 25°C 
for 30 min.  To it, a solution of 0.10 g (0.29 mmol) of bromide 39 in 2 mL of DMF was added 
via cannula under argon, and the solution was stirred at 25°C for 24 h and 60°C for 48 h.  The 
solution was diluted with dichloromethane and washed with water, and brine, dried (MgSO4), 
concentrated, and column chromatographed on silica gel using a gradient mixture of chloroform 
and methanol to give 20 mg (15% yield) of compound 46 along with 30 mg of compound 26 
(tricyclic pyrone). Compound 53:  1H NMR δ 12.23 (bs, 1 H, NH), 10.49 (bs, 1 H, NH), 7.73 (s, 
1 H, C8’H), 6.11 (s, 1 H), 5.73 & 5.71 (2s, 1 H, 2 diastereomers at C12), 5.08 – 5.02 (m, 1 H, 
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C5aH), 4.45 (dd, J = 13, 6 Hz, 1 H, CH2N), 4.03 (dd, J = 13, 9 Hz, 1 H, CH2N), 2.50 (t, J = 14 
Hz, 1 H), 2.39 (s, 3 H, COMe), 2.20 (s, 3 H, Me), 2.06 – 1.94 (m, 2 H), 1.86 – 1.56 (m, 3 H), 
1.36 – 1.22 (m, 2 H), 0.87 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 173.4, 163.45 & 163.41, 162.7, 
161.9, 157.0, 153.4, 148.2, 143.6, 132.1, 112.5, 109.9, 99.9, 97.5, 79.4 & 79.2, 51.4 & 51.3, 39.2 
& 39.17, 38.5 & 38.4, 36.7, 32.3 & 32.2, 30.8 & 28.3, 24.8, 20.3, 13.6 & 13.5.  HRMS calcd for 
C23H26N5O5 (M+H+) 452.1934, found 452.1917. 2D NOESY spectrum shows correlation 
between δ 7.73 with 4.45 and 4.03 ppm signals. 
 
(5aS,7S)-7-[(1R) and (1S)-2-[(N1-thyminyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9- 
tetrahyro-1-oxopyrano[4,3-b][1]benzopyran (45) 
O
O
O
H
N NH
O
O
 
To a solution of 14 mg (0.35 mmol) of NaH in 2 mL of DMF under argon was added 45 
mg (0.35 mmol) of thymine at 25°C, and the solution was stirred for 1 h.  To it was added a 
solution of 0.10 g (0.29 mmol) of bromide 39 in 1 mL of DMF via cannula.  The reaction 
solution was stirred at 25°C for 24 h and 80°C for 24 h, cooled to 25°C, and added 9 µL of acetic 
acid.  DMF was removed under vacuum at 50°C, and the resulting solid was column 
chromatographed on silica gel using a gradient mixture of dichloromethane and methanol as 
eluent to give 45 mg (42 % yield) of compound 45. 1H NMR δ 9.17 (bs, 1 H, NH), 6.94 (s, 1 H, 
C6’H), 6.07 (s, 1 H), 5.70 (s, 1 H), 5.10 – 5.00 (m, 1 H, C5aH), 3.82 (dd, J = 13, 6 Hz, 1 H, 
CH2N), 3.40 (dt, J = 13, 9 Hz, 1 H, CH2N), 2.50 – 2.42 (m, 1 H), 2.18 (s, 3 H, Me), 2.10 - 1.50 
(m, 5 H), 1.91 (s, 3 H, Me), 1.34 - 1.12 (m, 2 H), 0.89 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 164.2, 
163.4, 162.7, 161.8, 151.1, 140.7 & 140.6, 132.1, 110.9 & 110.8, 109.84 & 109.80, 99.9, 97.5, 
79.4 & 79.2, 52.3 & 52.1, 39.1, 38.4 & 38.2, 37.5 & 37.4, 36.7 & 36.4, 32.3 & 32.2, 30.9 & 28.1, 
20.3, 13.5 & 12.5.  HRMS calculated for C21H25N2O5 (M+H+) 385.1763, found 385.1760. 2D 
NOESY spectrum shows correlation between C6’-H of thymine (δ 6.94) with CH2N (3.82 and 
3.40) signals. 
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(5aS,7S)-7-[(1R) and (1S)-2-(2-Amino-9H-purin-9-yl)-1-methylethyl]-3-methyl 
1H,7H- 5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran  (47) 
 
O
O
O
H
N
NN
N NH2  
 
To a solution of 96 mg (0.29 mmol) of Cs2CO3 in 1 mL of DMF under argon at 25°C was 
added 40 mg (0.29 mmol) of 2-aminopurine, and the solution was stirred for 1 h.  This solution 
was then added to a solution of 0.10 g (0.29 mmol) of bromide 39 in 2 mL of DMF via cannula.  
The reaction solution was stirred at 25°C for 24 h, and DMF was removed under vacuum 
distillation at 50°C/0.1 mm Hg.  The resulting residue was subjected to a silica gel column and 
eluted with a gradient mixture of methylene chloride and methanol to give 56 mg (48% yield) of 
compound 47 (as two diastereomers at C12). Compound 47: 1H NMR δ 8.66 (s, C6’H), 7.72 & 
7.71 (2s, C8’H, 2 diastereomers), 6.07 (s, 1 H), 5.70 (s, 1 H), 5.29 (2, 2 H, NH2), 5.00 (dt, J = 11, 
5 Hz, 1 H, C5aH), 4.09 (dd, J = 8, 6 Hz, 1 H, CH2N), 3.90 (m, 1 H, CH2N), 2.46 (t, J = 14 Hz, 1 
H), 2.18 & 2.17 (2s, 3 H, Me), 2.13 - 1.80 (m, 2 H), 1.73 - 1.42 (m, 3 H), 1.38-1.16 (m, 2 H), 
0.87 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 163.3 & 163.2, 162.5, 161.8, 160.0, 153.64 & 153.61, 
149.7, 142.9, 132.0, 128.1, 109.7 & 109.6, 99.8, 97.4, 79.3 & 79.1, 47.1, 39.1, 38.1 & 38.0, 37.9 
& 37.88, 36.2, 32.2 & 32.0, 31.0, 29.8, 27.8, 21.5, 20.2, 13.8 & 13.7.  HRMS calcd for 
C21H24N5O3 (M+H+) 394.1879, found 394.1879.  2D NOESY spectrum shows correlation 
between δ 7.72 with 4.09 and 3.90 ppm signals. 
 
4-bromo-6-methyl-2H-pyran-2-one (49) 
OO
Br  
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To 10 mL of dry DMF under argon atmosphere was dropwise added the solution of PBr3 
in ether (8.734 g, 32 mmol in 18 mL ether) at 0°C. Then, a solution of 1.0 g (8.0 mmol) of 4-
hydroxy-6-methyl-2-pyrone 24 in 8 mL DMF was transferred to the above PBr3 solution. The 
resultant solution was heated to 60°C for 12 h. The resultant solution was cooled to 0°C and 
quenched with water, extracted with diethyl ether three times. Combined organic layer was 
washed with brine and dried over MgSO4 and concentrated.  Column chromatography on silica 
gel using the gradient mixture of hexane and diethyl ether gave 1.251g of 49 (83% yield). 1H 
NMR (CDCl3) δ 6.33 (bs, 1 H), 6.13 (bs, 1 H), 2.16 (s, 3 H); 13C NMR δ 162.1, 160.4, 141.1, 
114.5, 108.3, 19.6. 
 
4-azido-6-methyl-2H-pyran-2-one (50) 
OO
N3  
To the vacuum dried mixture of 0.32 g (11.561 mmol) of bromide 49 and 0.152 g ((2.34 
mmol) of NaN3 was added 5 mL of DMF and stirred at room temperature for 3 h under argon 
atmosphere. Water was added to the reaction and extracted with diethyl ether three times. 
Combined organic layer was washed with brine and dried over MgSO4 and concentrated.  
Column chromatography on silica gel using the gradient mixture of hexane and diethyl ether 
gave 0.204 g of 50 (87% yield). 1H NMR (CDCl3) δ 5.76 (s, 2 H), 2.26 (s, 3 H) 13C NMR δ 
163.9, 162.6, 156.4, 99.1, 96.9, 19.9.  
 
4-amino-6-methyl-2H-pyran-2-one (51) 
 
OO
NH2  
In a round bottom flask, taken 0.204 g of azide 50 (1.35 mmol) and vacuum flame dried 
thoroughly, purge argon and added 6 mL of dry ethanol via syringe. If not completely soluble, 
warm a little. Open under stream of argon and added 0.021 g of 10% Pd/C. Hydrogen balloon 
was fitted on top and stir the reaction mixture for 2 h. Reaction was monitored was TLC. The 
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reaction was filtered through celite and further washed with ethanol. Organic solvent was 
removed through rotary evaporator to give 0.168 g of amine (51) (100%). 1H NMR (CDCl3) δ 
5.58 (s, 1 H), 5.14 (s, 1 H), 4.25 - 4.4 (bs, 2H), 2.19 (s, 3H); 13C NMR (DMSO) δ 163.69, 
161.47, 159.84, 98.68, 80.47, 19.54.  
 
(5aS,7S)- 3-Methyl-7-(prop-1-en-2-yl)-6,7,8,9-tetrahydro-1H-pyrano[4,3-b]quinolin-1-one 
(52) 
 
O
N
O
 
 
(5aS,7S)- 3-methyl-9-(prop-1-en-2-yl)-7,8,9,10-tetrahydro-1H-pyrano[4,3- c]isoquinolin-1-
one (53) 
 
O
N
O
 
 
A solution of 0.17 g (1.34 mmol) of 4-amino-6-methyl-2-pyrone (51), 0.34 g (2.28 mmol) 
of (S)-perillaldehyde (25), and 35 mg (0.15 mmol) of 10-camphorsulfonic acid in 12 mL of 
toluene was stirred at 85°C under argon for 3 days.  The reaction solution was cooled to 25°C, 
diluted with ethyl acetate, washed with aqueous NH4OH, and brine, dried (MgSO4), 
concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and 
diethyl ether as eluents to give 63 mg (18% yield) of compound 52 and 62 mg (18% yield) of 
compound 53, along with 0.11 g of (S)- perillaldehyde.  Compound 52: [α]22D = -59.0° (c 0.10, 
CHCl3);  1H NMR δ 8.17 (s, 1 H, C10H), 6.45 (s, 1 H, C4H), 4.82 (s, 1 H, =CH2), 4.77 (s, 1 H, 
=CH2), 3.18 (dd, J = 18, 5 Hz, 1 H), 3.00 - 2.82 (m, 3 H), 2.60 – 2.42 (m, 1 H), 2.32 (s, 3 H, Me), 
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2.15 ~ 2.02 (m, 1 H), 1.83 (s, 3 H, Me), 1.78 – 1.62 (m, 1 H); 13C NMR δ 165.6, 163.2, 158.0, 
152.6, 147.9, 137.3, 131.8, 114.3, 110.2, 105.7, 41.0, 38.8, 28.3, 27.3, 21.1, 20.2.  HRMS 
calculated for C16H18NO2 (M+H+) 256.1338, found 256.1351. Compound 53:  [α]22D = -76.5o (c 
0.09, CHCl3);  1H NMR δ 8.76 (s, 1 H, C10H), 6.83 (s, 1 H, C4H), 4.89 (s, 1 H, =CH2), 4.77 (s, 1 
H, =CH2), 3.82 (dd, J = 21, 5 Hz, 1 H), 3.22 (dd, J = 21, 5 Hz, 1 H), 3.06 - 2.92 (m, 1 H), 2.58 – 
2.37 (m, 1 H), 2.40 (s, 3 H, Me), 2.20 ~ 2.03 (m, 2 H), 1.86 (s, 3 H, Me), 1.80 – 1.65 (m, 1 H); 
13C NMR δ 162.3, 157.5, 156.2, 154.5, 151.0, 148.3, 132.1, 114.5, 110.3, 106.5, 41.1, 33.8, 27.3, 
26.3, 20.9, 19.8.  HRMS calculated for C16H18NO2 (M+H+) 256.1338, found 256.1337. 
 
4-hydroxy-1-(4-methoxybenzyl)-6-methylpyridin-2(1H )-one (55) 
 
N
OH
O
OMe
 
 
A solution of 2.0 g (16 mmol) of pyrone 24 and 2.2 g (16 mmol) of 4-
methoxybenzylamine (54) in 30 mL of ethanol was reflux for 24 h, cooled to 25°C, and ethanol 
was removed under vacuum.  Crystallization the resulting solid in ethyl acetate gave 1.65 g of 4-
hydroxy-1-(4-methoxybenzyl)-6-methylpyridin-2(1H)-one (55). The mixture was dissolved in 
ethyl acetate (70 mL) and washed with 2 N HCl (20 mL), water, and brine, dried (MgSO4), 
concentrated to give 1.01 g (26% yield) of pure 55. This material was used in the following step 
without further purification.  Compound 55:  1H NMR δ 7.08 (d, J = 8 Hz, 2 H), 6.83 (d, J = 8 
Hz, 2 H), 6.08 (s, 1 H), 5.86 (s, 1 H), 5.24 (s, 2 H, CH2N), 3.77 (s, 3 H, OMe), 2.24 (s, 3 H, Me); 
13C NMR (DMSO-d6) δ 165.9, 164.1, 158.2, 147.7, 129.6, 127.7 (2 C), 114.0 (2 C), 100.5, 96.0, 
55.0, 44.8, 19.9.  HRMS calculated for C14H16NO3 (M+H+) 246.1125, found 246.1133. 
 
(5aS,7S)-2-(4-methoxybenzyl)-3-methyl-7-(prop-1-en-2-yl)-6,7,8,9-tetrahydro-2Hchromeno[ 
3,2-c]pyridin-1(5aH)-one (56) 
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A solution of 1.0 g (4.1 mmol) of compound 55, 0.61 g (4.1 mmol) of (S)-perillaldehyde 
(25), 0.35 g (4.1 mmol) of piperidine, and 0.24 g (4.1 mmol) of acetic acid in 30 mL of 
chloroform was reflux for 12 h, cooled to 25°C, diluted with ethyl acetate, washed with aqueous 
NH4Cl, and brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using 
a gradient mixture of hexane and ethyl acetate as eluents to give 1.38 g (90% yield) of compound 
56.  [α]22D = +5.7o (c 0.18, CHCl3);  1H NMR δ 7.10 (d, J = 8 Hz, 2 H), 6.82 (d, J = 8 Hz, 2 H), 
6.38 (s, 1 H), 5.67 (s, 1 H), 5.21 (s, 2 H, CH2N), 5.10 – 5.00 (m, 1 H, C5aH), 4.74 (s, 2 H, 
=CH2), 3.77 (s, 3 H, OMe), 2.58 – 2.47 (m, 1 H), 2.22 (s, 3 H, Me), 2.20 – 2.00 (m, 2 H), 1.90 - 
1.61 (m, 2 H), 1.74 (s, 3 H, Me), 1.44 – 1.22 (m, 2 H);  13C NMR δ 161.5, 159.8, 158.8, 148.2, 
145.3, 131.7, 129.1, 127.9 (2 C), 114.1 (2 C), 111.3, 109.5, 103.7, 100.3, 78.2, 55.3, 46.3, 43.4, 
39.9, 32.4, 31.9, 20.8, 20.7.  HRMS calculated for C24H28NO3 (M+H+) 378.2069, found 
378.2050. 
 
(5aS,7S)-2-(4-methoxybenzyl)-3-methyl-7-[(1R) and (1S)-1-hydroxypropan-2-yl]-6,7,8,9-
tetrahydro-2H-chromeno[3,2-c]pyridin-1(5aH)-one (57) 
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To a cold (-20°C) solution of 1.15 g (3.06 mmol) of compound 56 in 20 mL of THF 
under argon was added 1.53 mL (1.53 mmol) of BH3•THF (1.0 M in THF).  After standing at -
20°C for 4 days, the reaction solution was stirred at 0°C, and 10 mL of 0.5% aqueous NaOH and 
5 mL of 30% H2O2 were added.  The solution was stirred at 0°C for 2 h, diluted with ethyl 
acetate, washed with aqueous NH4Cl, and brine, dried (MgSO4), concentrated, and column 
chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate as eluents to 
give 0.79 g (69% yield; based on reacted 56) of 57.  Compound 57:  1H NMR δ 7.08 (d, J = 8 
Hz, 2 H), 6.81 (d, J = 8 Hz, 2 H), 6.33 (s, 1 H), 5.64 (s, 1 H), 5.19 (s, 2 H, CH2N), 5.15 – 4.96 
(m, 1 H, C5aH), 3.75 (s, 3 H, OMe), 3.58 – 3.44 (m, 2 H, CH2O), 2.47 (d, J = 12 Hz, 1 H), 2.24 
– 2.18 (m, 1 H), 2.19 (s, 3 H, Me), 2.11 – 1.94 (m, 3 H), 1.75 - 1.46 (m, 2 H), 1.22 – 1.02 (m, 1 
H), 0.88 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 161.7, 160.0, 158.9, 145.3, 132.5, 129.2, 128.0 (2 
C), 114.3 (2 C), 111.1, 103.9, 100.5, 78.7 & 78.6 (2 diastereomers), 66.0 & 65.9, 55.5, 46.5, 
40.25 & 40.21, 39.5 & 37.1, 37.5 & 37.3, 32.6 & 32.5, 31.3 & 28.7, 20.9, 13.4 & 13.3.  The 
signal intensities indicate the ratio of two diastereomers is 1:1. HRMS calculated for C24H30NO4 
(M+H+) 396.2175, found 396.2192. 
 
(5aS,7S)-2-(4-methoxybenzyl)-3-methyl-7-[(1R) and (1S)-(2-methanesulfonyloxy)-1- 
methylethyl]-6,7,8,9-tetrahydro-2H-chromeno[3,2-c]pyridin-1(5aH)-one (58) 
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To a cold (0°C) solution of 0.13 g (0.33 mmol) of alcohol 57 and 0.14 mL (0.97 mmol) 
of triethylamine in 4 mL of dichloromethane was added 38 µL (0.49 mmol) of methanesulfonyl 
chloride under argon.  The reaction solution was stirred at 0°C for 2 h, diluted with 
dichloromethane, washed with aqueous NaHCO3, and brine, dried (MgSO4), concentrated, and 
column chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate as 
eluents to give 0.12 g (79% yield) of mesylate 58.  1H NMR δ 7.10 (d, J = 8 Hz, 2 H), 6.83 (d, J 
= 8 Hz, 2 H), 6.38 (s, 1 H), 5.66 (s, 1 H), 5.21 (bs, 2 H, CH2N), 5.06 – 4.98 (m, 1 H, C5aH), 4.21 
– 4.08 (m, 2 H, CH2O), 3.78 (s, 3 H, OMe), 3.03 (s, 3 H, MeS), 2.52 (d, J = 14 Hz, 1 H), 2.22 (s, 
3 H, Me), 2.20 – 2.18 (m, 2 H), 1.94 – 1.85 (m, 1 H), 1.78 - 1.52 (m, 3 H), 1.32 – 1.12 (m, 1 H), 
1.00 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 161.6, 159.8, 158.8, 145.5, 131.6, 129.1, 128.0 (2 C), 
114.2 (2 C), 111.5, 103.6, 100.2, 78.1 & 78.0 (2 diastereomers), 72.4, 55.4, 46.4, 38.9, 37.5 & 
37.4, 37.35, 37.2 & 37.1, 37.0, 32.2 & 32.1, 30.8 & 28.6, 20.8, 13.3 & 13.2.  The signal 
intensities indicate the ratio of two diastereomers is 1:1. HRMS calculated for C25H32NO6S 
(M+H+) 474.1950, found 474.1945. 
 
(5aS,7S)-2-(4-Methoxybenzyl)-7-((2R) and (2S)-1-(6-amino-3H-purin-3-yl)propan-2-yl)-3- 
methyl-6,7,8,9-tetrahydro-2H-chromeno[3,2-c]pyridin-1(5aH)-one (59) 
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A solution of 0.12 g (0.25 mmol) of mesylate 58 and 34 mg (0.25 mmol) of adenine in 2 
mL of DMA was heated at 150°C under argon for 10 h, cooled to 25°C, diluted with 
dichloromethane and washed with water, and brine, dried (anhydrous Na2SO4), concentrated, and 
column chromatographed on silica gel using a gradient mixture of hexane, ethyl acetate, 
dichloromethane, and methanol as eluents to give 23 mg (18% yield) of 59. 1H NMR δ 8.06 (s, 1 
H, C2’H), 7.99 (s, 1 H, C8’H), 7.10 (d, J = 8 Hz, 2 H), 6.82 (d, J = 8 Hz, 2 H), 6.39 (s, 1 H), 5.66 
(s, 1 H), 5.21 (bs, 2 H, CH2N), 5.06 – 4.94 (m, 1 H, C5aH), 4.51 (dd, J = 13, 6 Hz, 1 H, CH2N), 
4.08 (dd, J = 13, 9 Hz, 1 H, CH2N), 3.77 (s, 3 H, OMe), 2.60 – 2.30 (m, 2 H), 2.11 (s, 3 H, Me), 
2.20 – 2.18 (m, 2 H), 1.98 – 1.55 (m, 2 H), 1.50 - 1.20 (m, 2 H), 0.90 (d, J = 7 Hz, 3 H, Me); 13C 
NMR δ 161.7, 159.9, 158.9, 154.6, 152.8, 150.4, 145.6, 143.2, 131.5, 129.1, 128.0 (2 C), 119.7, 
114.3 (2 C), 111.7, 103.7, 100.4, 78.2, 55.5 & 54.7, 46.6, 39.1 & 36.2, 38.3, 37.2, 32.1 & 31.0, 
29.9 & 27.8, 22.7 & 21.8, 21.0 & 20.8, 13.4.  The signal intensities indicate the ratio of two 
diastereomers is 1:1. HRMS calculated for C29H33N6O3 (M+H+) 513.2614, found 513.2627. 2D 
NOESY spectrum shows NOE correlation between C2’-H (δ 8.08 ppm) and CH2N (4.51 and 
4.08 ppm) signals. 
 
4-hydroxy-6-methyl-2-pyridone (61) 
 
H
N
OH
O
 
 
In a 10 ml round bottom flask, taken 250 mg (1.98 mmol) of pyrone 24 dissolved in 1 mL 
of 28% NH4OH and mixture was refluxed at 100°C for 6 h. Reaction was allowed to cool to 
  55 
room temperature. Solid was separated by filtration and recrystallized from ethanol in 81% yield 
as a yellow solid 61. M.P. 322°C; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.87 (bs, 1H), 5.7 (s, 
1H), 5.3 (s, 1H), 2.1 (s, 3 H); 13C NMR δ 167.6, 164.8, 146, 98.2, 95.8, 18.5. 
 
(7S)-6,7,8,9-tetrahydro-3-methyl-7-(prop-1-en-2-yl)-2H-chromeno[3,2-c]pyridin-1(5aH)-
one (62) 
 
H
N
O
O
H
 
 
A solution of 250 mg (2.0 mmol) of compound 61, 300 mg (2.0 mmol) of (S)-
perillaldehyde 25, 170 mg (2.0 mmol) of piperidine, and 120 mg (2 mmol) of acetic acid in 15 
mL of chloroform was reflux for 12 h, cooled to 25°C, diluted with methylene chloride, washed 
with aqueous NH4Cl, and brine, dried (MgSO4), concentrated, and column chromatographed on 
silica gel using a gradient mixture of hexane and ethyl acetate as eluents to give 500 mg (97% 
yield) of compound 62. 1H NMR (CDCl3, 1H NMR (CDCl3) δ 12.66 (bs, 1H), 6.3 (s, 1H), 5.64 
(s, 1H), 5.1 (dd, J = 11 Hz, 5Hz, 1H), 4.75 (m, 1H, =CH), 4.73 (m, 1H, =CH), 2.48 (ddd, J 
=14Hz, 4Hz, 2.4Hz, 1H), 2.23 (s, 3H), 2.22-2.02 (m, 3H), 1.88-1.72 (m, 2H), 1.74(s, 3H, MeC=), 
1.31 (ddd, J = 25Hz, 12.8Hz, 4Hz, 1H); 13C NMR δ 163.2, 162.4, 148.4, 144.8, 131.7, 110.4, 
109.6, 103.4, 99.1, 78.5, 43.6, 40.0, 32.5, 32.1, 20.9, 19.3. 
 
(7S)-tert-butyl-6,7,8,9-tetrahydro-3-methyl-1-oxo-7-(prop-1-en-2-yl)-1H-chromeno[3,2-
c]pyridine-2(5aH)-carboxylate (63) 
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N
O
O
OO
H
 
 
Taken 200 mg of pyridinone 62 (0.78 mmol) and 19 mg of DMAP (0.15 mmol) together 
in a round bottom flask and vacuum flame dried, purge argon and added 3 mL of acetonitrile. 
Added 273 µl of dry triethylamine (1.94 mmol) via syringe and cool to 0°C and stir for 30 
minutes. Open quickly and added 340 mg of (Boc)2O  (1.55 mmol) and warm to room 
temperature by stirring for 24 h.  Dilute with water and extract ethyl acetate twice. Combine 
ethyl acetate washed with brine, dried over sodium sulfate, column chromatographed to give 268 
mg of 63  (97%). 1H NMR (CDCl3) δ 6.3 (s, 1H), 5.95 (s, 1H), 5.1 (dd, J = 11 Hz, 5Hz, 1H), 
4.75 (m, 1H, =CH), 4.73 (m, 1H, =CH), 2.48 (ddd, J=14Hz, 4Hz, 2.4Hz, 1H), 2.31 (s, 3H) 2.22-
2.02 (m, 3H), 1.88-1.72 (m, 2H), 1.74(s, 3H, MeC=), 1.5 (s, 9H), 1.31 (ddd, J = 25Hz, 12.8Hz, 
4Hz, 1H); 13C NMR δ 161.9, 156.6, 152.13, 151.1, 147.7, 137.3, 109.7,109.0, 109, 106.2, 83.6, 
78.0, 43.1, 39.9, 32.7, 31.7, 27.6, 24.1, 20.1. 
 
(7S)-tert-butyl-6,7,8,9-tetrahydro-7-((R)-1-hydroxypropan-2-yl)-3-methyl-1-oxo-1H-chro 
meno[3,2-c]pyridine-2(5aH)-carboxylate (64) 
 
N
O
O
OO
OH
H
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To a cold (-20°C) solution of 265 mg (0.74 mmol) of compound 63 in 6 mL of THF 
under argon was added 0.37 mL (0.37 mmol) of BH3•THF (1.0 M in THF).  After standing at -
20°C for 2 days, the reaction solution was stirred at 0°C, and 2 mL of 0.5% aqueous NaOH and 1 
mL of 30% H2O2 were added.  The solution was stirred at 0°C for 2 h, diluted with ethyl acetate, 
washed with aqueous NH4Cl, and brine, dried (MgSO4), concentrated, and column 
chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate as eluents to 
give 62 mg (65% yield; based on reacted 63) of 64 as a mixture of two diastereomers at C12 
(1:1; based on 13C NMR spectrum). 1H NMR (CDCl3) δ 6.38 (s, 1H), 5.96 (s, 1H), 5.05-5.00 (t, 
J= 5.2 Hz, 1H), 3.62 – 3.52 (m, 2H, CH2O), 2.46 (m, 1H), 2.34 (s, 3H, Me), 2.13 – 1.99 (m, 2H), 
1.73 – 1.51 (m, 3H), 1.54 (s, 9H), 1.19 – 1.12  (m, 2H), 0.90 (d, J=7 Hz, 3H, Me); 13C NMR  
(two diastereomers) δ 162.1, 156.7, 152.2, 151.2, 138.1, 109.2, 108.8, 106.5, 83.9, 78.4, 
65.7,40.0, 39.5, 37.2, 32.8, 31.01, 27.8, 24.2, 13.5 and13.2 (Me of two diastereomers). 
 
(R)-2-((7S)-2-(tert-butoxycarbonyl)-2,5a,6,7,8,9-hexahydro-3-methyl-1-oxo-1H-
chromeno[3,2-c]pyridin-7-yl)propyl methanesulfonate (65) 
 
N
O
O
OO
OMs
H
 
 
To a cold (0°C) solution of 400 mg (1.11 mmol) of alcohol 64 and 0.47 mL (3.34 mmol) 
of triethylamine in 8 mL of dichloromethane was added 129 µL (1.67 mmol) of methanesulfonyl 
chloride under argon.  The reaction solution was stirred at 0°C for 2 h, diluted with 
dichloromethane, washed with aqueous NaHCO3, and brine, dried (MgSO4), concentrated, and 
column chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate as 
eluents to give 382 mg (79% yield) of mesylate 65 as a mixture of two diastereomers at C12 
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(1:1; based on 13C NMR spectrum). 1H NMR (CDCl3) δ 6.31 (s, 1H), 5.89 (s, 1H), 5.05-5.00 
(m, J= 5.2 Hz, 1H), 4.15 – 4.08 (m, 2H, CH2O), 3.01 (s, 3H), 2.46 (m, 1 H), 2.27 (s, 3H, Me), 
2.13 – 1.99 (m, 2H), 1.73 – 1.51 (m, 3H), 1.54 (s, 9H), 1.19 – 1.12  (m, 2H), 0.90 (d, J=7 Hz, 
3H, Me); 13C NMR  (two diastereomers) δ 161.9, 156.5, 151.9, 150.9, 137.2, 108.9, 108.7, 106.0, 
83.7, 77.7 and 77.77.61 (two diastereomers), 72.2, 38.71, 37.02 and 37.8 (two diastereomers), 
36.7 and 36.6 (two diastereomers) 32.25 and 32.15 (two diastereomers), 31.48, 30.25, 28.1, 
27.51, 23.9, 12.98. 
 
(7S)-7-((R)-1-(6-amino-5,6-dihydropurin-3-yl)propan-2-yl)-6,7,8,9-tetrahydro-3-methyl-2H-
chromeno[3,2-c]pyridin-1(5aH)-one (66) 
 
H
N
O
O
H
N
N
N
N
NH2
 
 
 
(7S)-7-((R)-1-(6-amino-4H-purin-9(8H)-yl)propan-2-yl)-6,7,8,9-tetrahydro-3-methyl-
2H-chromeno[3,2-c]pyridin-1(5aH)-one (67) 
 
H
N
O
O
H
N
NN
N
NH2
 
 
A solution of 0.12 g (0.25 mmol) of mesylate 65 and 34 mg (0.25 mmol) of adenine in 2 
mL of DMA was heated at 150°C under argon for 10 h, cooled to 25°C, diluted with 
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dichloromethane and washed with water, and brine, dried (anhydrous Na2SO4), concentrated, and 
column chromatographed on silica gel using a gradient mixture of hexane, ethyl acetate, 
dichloromethane, and methanol as eluents to give 23 mg (18% yield) of 66 and 8 mg (6% yield) 
of 67. Compound 66 (more polar; 2 diastereomers at C12) 1H NMR δ 8.08 (s, H of adenine), 
7.98 and 7.97 (2s, 1H, H of adenine; 2 diastereomers), 6.30 (s, 1H), 5.63 and 5.62 (2s, 1H), 5.02 
(m, 1H, C5aH), 4.50 (dd, J=13, 6 Hz, 1H, CHN), 4.08 (2dd, J=13, 8 Hz, 1H, CHN; 2 
diastereomers), 2.46 (m, 2H), 2.25 and 2.24 (2s, 3H, Me; 2 diastereomers), 2.10–1.22 (a series of 
m, 6H), 0.91 (d, J=7Hz, 3H, Me); 13C NMR (2 diastereomers) δ 163.2 and 163.1, 162.4, 161.7, 
154.4,154.0, 150.7, 142.3, 131.7 and 131.6, 121.0, 199.8, 99.7, 97.3, 79.0, 78.8, 54.5 and 54.4, 
38.9, 38.1 and 38.0, 37.1 and 36.9, 36.1, 32.0 and 31.9, 30.7, 27.6, 20.1, 13.3 and 13.2. HRMS 
calcd for C21H24N5O3 (M+H) 394.1881, found 394.1875. 
 
4-hydroxy-6-methyl-3-((E)-(phenylimino)methyl)pyridin-2(1H)-one (68) 
 
H
NO
ONH
 
 
Taken 3.6 g of pyridinone 61 (23.98 mmol), 2.23 g of aniline (23.98 mmol), 15 mL of triethyl 
orthoformate together in a round bottom flask followed by addition of 20 mL of 3:1 DMF : 
AcOH and reflux at 130°C for 2 h. Color changes from yellow to brown. Cool to room 
temperature. Dilute brine and extract methylene chloride twice followed by extraction with 10% 
methanol in methylene chloride. Organic layer dried over sodium sulfate and crystallize from 
methylene chloride to obtain 3.81 g of 68 as yellow solid. 1H NMR (DMSO-d6) δ ppm 9.89 (bs, 
1H), 8.91 (d, 1H, E/Z isomer), 7.2-7.6 (m, 5H), 5.7 (s, 1H), 2.2 (s, 3H); 13C NMR (CDCl3) 185.1, 
166.9, 153.1, 150.3, 138.6, 130.2, 126.9, 118.6, 107.0, 20.2. 
  
1,2-dihydro-4-hydroxy-6-methyl-2-oxopyridine-3-carbaldehyde (69) 
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H
NO
OOH
H
NO
OHO  
 
Taken 3.41 g of pyridinone 68 and added 50 mL of 5% K2CO3 in water and reflux in open for 1 
h. Cool to room temperature. Acidify to pH ~1 by adding conc. HCl at 0°C. Filter the solid and 
crystallize from ethanol to yield 2.08 g of 69 (85%) as yellow solid. 1H NMR (DMSO-d6) δ ppm 
13.52 (bs, 1H), 11.73 (bs, 1H), 9.83 (bs, 1H), 5.86 (s, 1H), 2.2 (s, 3H). 13C NMR (DMSO-d6) 
193.3, 174.7, 163.3, 157.1, 105.3, 97.7, 19.6 
 
7-methyl-6H-pyrano[3,2-c]pyridine-2,5-dione (70) 
 
H
NO
O
O  
A mixture of 60 mg (.36 mmol) of aldehyde 69 and 146 mg (.43 mmol) of 
[(Methoxycarbonyl)methylene]triphenyl phosphorane (Wittig reagent) together in a round 
bottom flask and added freshly distilled toluene and reflux for 2 h. Color changes from yellow to 
purple. Cool to RT, precipitate formed, filter it, vacuum dried and crystallized from methanol to 
yield compound 70. Yield 55% as yellow solid. 1H NMR (400 MHz, DMSO-d6) d ppm 2.08 - 
2.39 (m, 1 H) 2.39 - 2.63 (m, 1 H) 3.10 - 3.48 (m, 2 H) 5.84 - 6.47 (m, 1 H) 7.35 - 7.73 (m, 1 H) 
7.92 (d, J=9.37 Hz, 1 H) 12.01(br. s, 1 H) 
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CHAPTER 2 - Insight into the inhibition of aggregation of 
Alzheimer’s Aβ  peptides and disaggregation of Aβ  oligomers using 
various biophysical techniques 
 
2.1 Introduction 
 
Neurodegenerative disease such as Alzheimer’s disease and Huntington’s disease involve 
the neuronal damage caused by the deposition of protein aggregates both extracellularly and 
intracellularly, which leads to abnormal brain function. The neurotoxicity of amyloid beta- (Aβ) 
peptide has been widely accepted as one of the fundamental causes of Alzheimer’s disease. Our 
goal is to study the inhibition of aggregation and disaggregation of oligomers and protofibrils 
using different tricyclic pyrone molecules such as CP2, in solution. In this chapter, I will discuss 
different biophysical techniques such as atomic force microscopy (AFM), surface plasmon 
resonance (SPR) spectroscopy, circular dichroism (CD) spectroscopy and protein quantification 
assay and use them to study the kinetics of aggregation of amyloid Aβ peptide and 
disaggregation of Aβ42 oligomers and protofibrils. Also, our objective is to search for the role of 
TP molecules in the counteraction of Aβ toxicity.   
2.2 Background 
 
Alzheimer’s disease (AD) is a cerebral degenerative disorder characterized by gradual 
loss of memory, impaired judgment etc. and is affecting 1% of the world population. AD 
involves two kinds to protein aggregates; (I) Extracellular aggregates, also known as neuritic 
plaques are composed of Aβ peptide aggregates, which are derived from the proteolytic 
processing of a transmembrane amyloid precursor protein (APP), by β- and γ- secretase 
enzymes. These Aβ aggregates tend to adopt β-sheet conformation.1 Amyloid plaque is 
deposited in cerebral blood vessels and cortex. (II) Intercellular aggregates, also known as 
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neurofibrillary tangles (NFT) is composed of phophorylated microtubule-associated tau protein 
and Aβ.2 In addition to that, the pathogenesis of AD is also related to genetic mutations 
responsible for familial forms of AD. The mutations could be in APP itself or in presenilin 1 
(PS1) and presenilin II (PS II).3 Although the detailed mechanism of Aβ aggregation is not fully 
resolved, a general hypothesis of Aβ aggregation is widely accepted and is as shown in Figure 
1.2.4 Aβ42 monomers rapidly oligomerize into paranuclei. Paranuclei themselves then can 
oligomerize to form larger, beaded protofibrils and fibrils. Monomers, paranuclei, and large 
oligomers are predominately unstructured but do contain β-sheet/ β-turn and helical (α) 
elements.4  
 
Amyloid fibrils are insoluble filamentous structures with width ~10 nm and length of 0.1-
10 µm. Using Solid State Nuclear Magnetic Resonance Spectroscopy, the β-sheet structure of 
Aβ(10-35) was revealed to have anti-parallel a β-sheet organization.5 Subsequently, it was found 
that full length Aβ(1-42) forms β-sheet structure with the same registry and orientation as shown 
in Figure 2.1.6 
 
 
Figure 2.1 Structural model for Aβ42 fibrils, (Taken from protein data bank, provided by Luhrs 
et al.).6 
 
Recent studies have suggested that intracellular Aβ oligomers rather than protofibrils or 
fibrils are the primary toxic species leading to the AD.7-8 It has been found that intracellular Aβ 
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aggregates are more toxic then the extracellular Aβ aggregates.9 Utilization of compounds that 
reduce the level of Aβ, prevent Aβ aggregation, and disaggregate existing Aβ aggregates has 
been proposed as a therapeutic strategy for AD. Different biophysical techniques including 
atomic force microscopy (AFM), circular dichroism (CD) spectroscopy, surface plasmon 
resonance (SPR) spectroscopy, and a protein quantification assays were used to study to study 
the mechanism of aggregation of Alzheimer Aβ peptide in solution phase as described in detail 
in the following sections.     
  
2.3 Biophysical experiments conducted to study the inhibition of aggregation  
of amyloid Aβ  peptides and disaggregation of Aβ  oligomers and protofibrils 
 
2.3.1 Use of atomic force microscopy to study the inhibition of aggregation and 
disaggregation of Aβ  peptide 
 
Atomic force microscopy (AFM) is a powerful tool to study the growth/kinetics and 
morphology of amyloid beta peptide, both in air/solid phase and in solution phase. AFM is used 
for the screening of small organic molecules as amyloid inhibitors along with other analytical 
techniques.  
 
2.3.1.1 Introduction and background  
AD involves the transformation of non-toxic soluble α-helical monomers into insoluble 
β-sheet fibrils. These insoluble fibrils are deposited in the extracellular part of the brain and 
along the walls of cerebral blood vessels as amyloid plaque.9 A significant amount of evidence 
suggests that these amyloid plaques play a central role in AD pathogenesis.9 Although electron 
microscopy and X-ray diffraction studies revealed the structure and morphology of beta sheet 
fibrils, they were unsuccessful in providing any insight on the structure and mechanism of 
aggregation.11,12 On the other hand, AFM studies have shown the presence of different 
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intermediates such as small soluble oligomers, large oligomers and protofibrils. In 1990s, AFM 
was used by Oda et al. to study the inhibition of Aβ fibrils formation by clusterin.13 Lansbery et 
al. used the AFM and showed the formation and structure of Aβ protofibrils.14-15 Recently, 
McLaurin et al. published an extensive data on the structure of soluble Aβ 40 oligomers.16 Using 
AFM, Liu et al. reported that amino acid residues 17-20 and 30-35 play a critical role in the 
formation of oligomers and protofibrils.17 Our primary focus is to make use of AFM 
spectroscopy and study the effect of TP compounds on Aβ inhibition of aggregation and 
disaggregation of soluble oligomers and protofibrils. 
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2.3.1.2 Preparation of Aβ40 stock solution 
A stock solution was prepared by dissolving 0.2 mg of Aβ40 (0.046 µmol) in 50 µL of 
DMSO (purchased from BACHEM, Bachem California Inc. Torrance, CA). 10 µL of Aβ40 was 
taken and diluted it with 90 µL of phosphate buffer (50 mM Na2HPO4 and 100 mM NaCl, pH 
7.4, filtered through "Fischer brand PTFE 0.2 µm) and 100 µL of deionized distilled water 
(filtered through "Fischer brand PTFE 0.2 µm) to make the total volume to 200 µL. Solution was 
ultra centrifuged and filtered through a 10,000 molecular weight cutoff ("microcon centrifugal 
filter devices" purchased from Millipore Corporation, Bedford, MA) at 13,000 r.p.m and 4ºC for 
30 minutes and was used for different experiments.18 
 
2.3.1.3 Preparation of Aβ42 stock solution 
A stock solution was prepared by dissolving 0.25 mg of Aβ42 in 150 µL (0.055 µmol) of 
DMSO (purchased from CALBIOCHEM, CAT# PP69)). A small aliquot, 20 µL of Aβ42 
(0.0073 µmol) was taken and diluted it with 80 µL of phosphate buffer (50 mM Na2HPO4 and 
100 mM NaCl, pH 7.4, filtered through "Fischer brand PTFE 0.2 µm pore size) and 100 µL of 
deionized distilled water (filtered through "Fischer brand PTFE 0.2 µm pore size) to make the 
total volume up to 200 µL. Solution was ultra centrifuged and was filtered through a 10,000 
molecular weight cutoff ("microcon centrifugal filter devices" purchased from Millipore 
Corporation, Bedford, MA) at 13,000 r.p.m and 4ºC for 30 minutes and was used as is for 
different experiments.18 
 
2.3.1.4 AFM instrumentation and sample preparation  
A Nanoscope IIIa SPM AFM (Digital Instruments Inc., Santa Barbara, CA, USA) 
workstation equipped with a multimode head using E-series or J-series piezoceramic scanner 
(Digital Instruments, Santa Barbara, CA). AFM probes were silicon nitride microcentilevers with 
300kHz resonance frequency and 40 N/m spring constant model images were acquired at scan 
rate of 0.5-1 Hz. Prior to sample preparation, all the stock solutions were vortexed for 30-45 
seconds. From the aliquot, 10 µL sample was removed and immediately spotted on freshly 
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cleaved micas. After waiting for 60-90 seconds, unbound Aβ peptide was washed with water 
twice (80 µL each), and dried with argon. AFM images were collected using a tapping mode 
with a high-aspect ration tip (Veeco Nanoprobe TM tips, Model TESP-HAR; Nanoscience 
Instruments, Inc., Phoenix, AZ, USA). Image J software at an 8-bit resolution was used to carry 
out grain analysis to collect quantitative data. The image was adjusted by setting a threshold so 
that no noise on the image was present. The same threshold was used for all other images in the 
same independent experiment. The drive amplitude and force constant were adjusted, to 
minimize the force of interaction between the tip and the mica surface, thus limiting the sample 
deformation. For each experiment, 25 µm2 images from three independent AFM scans were used 
to determine the density (particles/field) of monomers/ oligomers and protofibrils.18 
 
2.3.1.5 Inhibition of aggregation of Aβ40 with several compounds 
In vitro MC65 cell assay demonstrated the efficacy of CP2 as an amyloid inhibitor.19,20 
We studied the inhibition effect of two equivalents of CP2 and compared it with thioflavin T, 
curcumin and Congo red. A stock solution of 200 µL as explained in 2.3.1.2 was prepared and 
divided into five different vials (30 µL, 37 µM) and two equivalents of different compounds such 
as CP2, TP17, curcumin, congo red and TP17 (Figure 2.2) were added. After 24 h and 48 h, a 
small aliquot was taken and AFM images were captured. Different areas of the mica were 
scanned and representative images are shown in Figure 2.3.18 
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Figure 2.2. Structure of CP2, TP4, TP17, thioflavin T, Congo red and curcumin. 
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Figure 2.3. AFM images of inhibition of aggregation of Aβ40 monomers (Scale bar 1 µm). 
 
 
2.3.1.6 Inhibition of aggregation of Aβ42 with several compounds  
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Since the hydrophobicity of Aβ42 is more than Aβ40, it  aggregates fast in buffer 
solution and is thus more toxic. Similar to Aβ40 inhibition of aggregation studies, we studied 
Aβ42 inhibition of aggregation. A stock solution of 200 µL as explained in 2.3.1.3 was prepared 
and divided into five different vials (30 µL, 37 µM) and two equivalents of different compounds 
such as CP2, TP17, curcumin, Congo red etc. were added. After 24 h and 48 h, a small aliquot 
was taken and AFM images were captured. Different areas were scanned and representative 
images are shown in Figure 2.4. CP2, Congo red and curcumin have similar inhibitory activities, 
while TP17 and thioflavin T are inactive.18 
 
 
Continued….
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Figure 2.4. AFM images of inhibition of aggregation of Aβ42 monomers. 
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2.3.1.7 Disaggregation of Aβ42 oligomers with several compounds 
A stock solution of 200 µL as explained in 2.3.1.3 was prepared. Stock solution was kept 
at 4ºC for 24 h and small aliquot was taken. AFM confirms the formation of small oligomers. 
Once oligomers formed, stock solution was divided into five different vials (30 µL, 37 µM) and 
two equivalents of different compounds such as CP2, TP17, curcumin, congo red etc. were 
added. Samples were stored at 4ºC to slow down the speed of aggregation. After 24 h and 48 h, a 
small aliquot was taken and AFM images were captured. Different areas were scanned and 
representative images are shown in Figure 2.5) CP2, congo red and curcumin have similar 
inhibitory activities, while TP17 and Thioflavin T are inactive.18 
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Figure 2.5. AFM images of disaggregation of Aβ42 oligomers. 
 
2.3.1.8 Disaggregation of Aβ42 protofibrils with CP2 
According to the proposed aggregation hypothesis, Aβ42 monomers tend to aggregate to 
form the soluble oligomers. If untreated, soluble oligomers aggregate further to form long 
protofibrils and fibrils. We studied the efficacy of CP2 on Aβ42 protofibril disaggregation. A 
stock solution of 200 µL was prepared as explained in 2.3.1.3. The stock solution was stored at 
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4°C for 4 days and AFM image was taken to confirm the formation of Aβ protofibrils. Once the 
protofibrils had formed, 30 µL of Aβ42 (37 µM) was taken and to it was added two equivalents 
of CP2. After the addition of CP2, the sample was stored at 25ºC for 24 h. After 24 h, a small 
aliquot was taken and AFM was recorded. Different areas were scanned and a representative 
image is shown in Figure 2.6.18 
 
 
Figure 2.6. AFM images of disaggregation of Aβ42 protofibrils; (a) Aβ42 protofibrils formed 
form the incubation of Aβ42 monomer (37 µM) at 4ºC for 4 days. (b) Incubation of Aβ42 
protofibrils with CP2 (two equivalents) for 24 h at room temperature. 
 
2.3.1.9 Disaggregation of Aβ42 oligomers with CP2 over the period of five days 
While performing the disaggregation of Aβ42 oligomers experiment, we found that the 
disaggregated Aβ42 monomers tend to re-aggregate to oligomers over time. We studied how 
much CP2 is needed to maintain the Aβ42 in monomeric form. Aβ42 (37 µM) oligomers were 
treated with 2, 5, and 10 equivalents of CP2 over a period of five days. Each day, a small aliquot 
(10 µL) was removed from the stock and AFM images were taken. Three representative images 
are used to calculate the particle density using Image J software and the results are summarized 
in Figure 2.7.18        
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Figure 2.7. Disaggregation of Aβ42 oligomers with different equivalents of CP2 over the period 
of five days. Quantitative analysis of particle density in 25 µm2. Aβ oligomeric density from 
three independent AFM scans was calculated using Image J program. 
 
2.3.1.10 Result and discussion 
Using AFM spectroscopy, we studied the efficacy of some compounds such as CP2 and 
TP4 synthesized in our laboratory and compared it with different commercially available 
amyloid beta inhibitors such as thioflavin T21, congo red22 and curcumin.23 Tricyclic pyrone 
molecule TP17 was used as a negative control.20 Different areas of the mica surface were 
scanned and a few representative pictures of the result of inhibition of aggregation of Aβ40 
(Figure 2.3) and Aβ42 (Figure 2.4), disaggregation of Aβ42 oligomers (Figure 2.5), 
disaggregation of Aβ42 protofibrils (Figure 2.6) with CP2, Thioflavin T, congo red, curcumin, 
TP17 were captured. Based on our previous results20, we predicted low affinities of thioflavin T 
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and TP17 to the Aβ oligomers and consistent results were obtained (Figure 2.5). Since Aβ40 is 
less hydrophobic than Aβ42, lower amounts of aggregates were formed (Figure 2.3). Bioactive 
compounds CP2, congo red and curcumin inhibits the extent of aggregation by about 50% over a 
period of 48 h, whereas no such inhibitory effect was observed for TP17 and thioflavin T 
(Figure 2.8). Also, when compared to the control, two equivalents of CP2, Congo red and 
curcumin are sufficient enough to slow down the speed of aggregation (Figure 2.9).18 
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Figure 2.8. Inhibition of aggregation of Aβ40 with two equivalents of CP2, TP17, thioflavin T, 
curcumin and congo red separately over 24 h and 48 h. Quantitative analysis of particle density 
in 25 µm2 AFM scans. Aβ oligomeric density from three independent AFM scans was calculated 
using Image J program. Error bars represent standard deviation. 
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Figure 2.9. Inhibition of aggregation of Aβ42 with two equivalents of CP2, TP17, thioflavin T, 
curcumin and congo red separately over 24 h and 48 h. Quantitative analysis of particle density 
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in 25 µm2 AFM scans. Aβ oligomeric density from three independent AFM scans was calculated 
using Image J program. Error bars represent standard deviation. 
 
  
It is widely accepted that Aβ oligomers are toxic to neurons and play a critical role in AD 
progression.7 Also, compared to Aβ42, Aβ40 is less toxic and thus we focused our studies on 
toxic Aβ42 oligomers and protofibrils.19 We investigated whether CP2, curcumin and congo red 
have similar effects on Aβ42 disaggregation of the toxic oligomers to non-toxic monomers. 
Aβ42 oligomers were grown based on a published protocol.24 Aβ42 oligomers were treated with 
two equivalents of different compounds such as CP2, thioflavin T, congo red, curcumin and 
TP17 and AFM images were recorded after 24 h and 48 h (Figure 2.5). Due to the size limitation 
of AFM, Aβ42 monomers and dimers (< 2 nm diameter) were too small to be observed. 
Different areas were scanned and image J software was used to calculate the peptide density 
(average three images) and the results are summarized in Figure 2.10. After 24 h and 48 h of 
incubation of different compounds in Aβ42 oligomers at 4°C, a 50% decrease in aggregates was 
observed for CP2, Congo red and curcumin. After 48 h, CP2 showed the greatest disaggregating 
ability. Curcumin had a greater disaggregation activity than congo red. Thioflavin T and TP17 
did not show disaggregation activities.18 
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Figure 2.10. Disaggregation of Aβ42 oligomers with two equivalents of CP2, TP17, thioflavin 
T, curcumin and congo red separately over 24 h and 48 h. Quantitative analysis of particle 
density in 25 µm2 AFM scans. Aβ oligomeric density from three independent AFM scans was 
calculated using Image J program. Error bars represent standard deviation. n =3, *p, **p, ***p, 
****p, *****p  < 0.01 compared with their respective controls. 
 
 
Surprisingly, after 24 h, disaggregated Aβ42 tends to re-aggregate over time and more 
aggregates were observed for CP2, curcumin and congo red over time (Figure 2.10). We studied 
the amount to CP2 required to maintain Aβ42 peptide in monomeric form (derived from the 
disaggregation of oligomers) without aggregation over 5 days. Hence, Aβ42 oligomers (37 µM) 
in pH 7.4 PBS solution were prepared (confirmed by AFM) and treated with various amounts of 
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CP2 and incubated at 4°C over 5 days (days 2–6). Each day, an aliquot was removed and AFM 
images were taken (in various locations of the mica), and three representative images were used 
to calculate the peptide particle density. The results are summarized in Figure 2.7. On day 4, 
protofibrils were observed in the Aβ42 solution without CP2, and on day 6, protofibrils 
predominated. It was observed that Aβ42 solutions incubated with 2 and 5 equivalents of CP2 
showed lesser amounts of oligomers after 24 h and 48 h but the oligomers size increased after 5 
days. On the other hand, in the presence of 10 equivalent of CP2, only ~8% of oligomers were 
observed compared with zero equivalent of CP2 after 5 days. The results suggest that 
disaggregated Aβ42 monomer and smaller oligomers tend to aggregate and can recombine to 
form larger oligomers over time It is suggestive that CP2 binds to Aβ oligomers and breaks apart 
the oligomers into small monomer and dimer. The binding of CP2 with monomeric Aβ and Aβ 
oligomers is reversible and Aβ42 monomer re-aggregates to form oligomers over time in a 
closed compartment.18  
Also, based on Aβ aggregation pathway (Figure 1.2) Aβ oligomers undergo nucleation 
polymerization and aggregate to form protofibrils, which have been revealed to be toxic to 
neuronal cells and to affect learning in mice.25,26 We studied the disaggregation of Aβ42 
protofibrils with CP2. Aβ42 protofibrils were produced by incubation of Aβ42 monomer in PBS 
for 4 days (confirmed by AFM). To preformed Aβ42 protofibrils, two equivalents of CP2 was 
added and incubated at 25°C for 24 h. After 24 h, a small aliquot was taken and AFM images 
revealed the disappearance of protofibrils and presence of small amounts of oligomers (figure 
2.6).        
Detailed AFM studies were conducted in our laboratory and the results have shown that 
CP2 inhibits the Aβ aggregation formation, disaggregates soluble oligomers to non-toxic 
monomers and protofibrils to small oligomers.18 
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2.3.2 Use of surface plasmon resonance spectroscopy to study the interaction of 
tricyclic pyrone and Aβ  peptide  
 
2.3.2.1 Introduction and background 
 
Surface plasmon resonance (SPR) is one of the most sensitive tools to detect the mass 
change above the gold-coated metal surface.27 SPR used to study the direct binding of protein-
protein, protein-compound, ligand-receptor, host-guest, and protein-antibody etc. interactions. In 
SPR spectroscopy, a change in the mass above the metal surface can be quantified in situ by 
monitoring a shift in SPR angle (Figure 2.11). A SPR spectrometer can sense the change in 
pg/mm2.28 
Aβ monomers polymerize to form insoluble fibrils, which are toxic to neurons. Previous 
studies indicate that Aβ polymerization involves interactions between the Aβ peptides.29 A 
pharmacological approach to prevent the amyloid formation is to use drugs that specifically 
disrupts the Aβ - Aβ interactions. Tjernberg et al. reported a small peptide ligands that can bind 
to the full length Aβ, and hinder Aβ-Aβ interaction thus inhibits aggregation. Their aim was to 
find a region of Aβ peptide, which is crucial for Aβ aggregation. Using SPR spectroscopy, they 
arrest the Aβ fibril formation by a pentapeptide ligand (beta sheet breakers) and confirmed it by 
AFM spectroscopy.30 Our goal is to study the binding affinity of TP compound CP2 to Aβ40 and 
Aβ42 monomers and small soluble oligomers (confirmed by AFM). 
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Figure 2.11. Schematic representation of SPR principle.28 (This picture is modified from the 
manufacturer’s handbook) 
 
2.3.2.2 Binding of CP2 and TP17 to Aβ40 and Aβ42 monomers  
A Biacore 3000 (Biacore Inc., Piscataway, NJ, USA), equipped with four flow cells in 
one sensor chip (CM5), was used for real-time binding studies. The Aβ40 and Aβ42 peptides 
were separately immobilized on gold sensor CM5 chips as described.31 First, carboxymethylated 
dextran of CM5 was activated with N-hydroxysuccinimide in pH 7.4 buffer, followed by the 
coupling with Aβ peptides. Free activated unreacted chip surface was blocked by ethanolamine. 
The resulting Aβ-bound sensor chip was used in the SPR studies, and the amounts of bound Aβ 
were measured from the SPR graph. The reference cells were prepared following the same 
procedure but without addition of Aβ peptides (Figure 2.12). 
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Figure 2.12. Immobilization of Aβ on to CM5 gold chip. (1) Activation and immobilization of 
Aβ on gold CM5 sensor chip. (2) The surface activated by EDC/NHS was exposed to a fresh 
Aβ40/ Aβ42 solution to form a peptide bond between the amine group on the peptide and the 
carboxylic group on the CM5 surface. (3) The deactivation of unreacted sites was achieved by 
blocking NHS-activations with ethanolamine.31 
 
 
CP2 and TP17 were dissolved in 50 mM Tris buffer to a concentration of 800 µM and 
injected into flow cells. The chip surface was exposed to compounds for 60 s, then to running 
buffer (10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.05% surfactant P20, pH 7.4) for 180 s. 
The response unit (RU) was recorded, converted to pmol bound compound, and analyzed (1RU = 
1 pmol). The flow cells were then regenerated with regenerating buffer containing urea, while 
leaving the immobilized Aβ peptides intact. The same chips with the same amounts of bound Aβ 
peptides were used for consecutive analysis of different compounds and comparisons were made 
only between the bindings to the same chips. The amounts of bound compounds were calculated 
by the ∆RU value, obtained by subtracting the RU at the time before compound injection from 
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the RU at the time just after the injection of running buffer. The ∆RU obtained from the 
reference cell was considered the background binding and was subtracted before the analysis 
(Figure 2.13).20  
 
 
Figure 2.13. Real-time detection of the binding of tricyclic pyrone to Aβ40 (A and B) and Aβ42 
(C and D) by SPR. The results from a typical experiment are shown. Color code: Blue is cell 
surface without immobilized Aβ and Red is cell surface with immobilized Aβ. 
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2.3.2.3 Binding of CP2 to Aβ42 oligomers using anti-oligomer antibody (AB9234) 
We have shown that in real time binding studies, CP2 binds to Aβ peptide. Also, AFM 
studies have shown that CP2 disaggregates Aβ42 oligomers to monomers but the mechanism of 
disaggregation is still unknown. In order to shed some light, we are interested in knowing if CP2 
binds to Aβ42 oligomers. For real time binding studies using SPR, injecting Aβ42 oligomers to 
the flow cell does not confirm the binding of the oligomers as it could be only the monomers that 
bound to the surface. We therefore modified our experiment and used AB9234 antibody as a host 
that binds to the activated gold surface of CM5 sensor chip.32 AB9234 is an anti amyloid 
oligomer antibody that specifically binds to all types of Aβ oligomers.33 A Biacore 3000 
(Biacore Inc., Piscataway, NJ, USA), equipped with four flow cells in one sensor chip (CM5), 
was used for real-time binding studies. Carboxymethylated dextran (CM5) of sensor chip is 
activated by injecting 200 µL of 1:1 mixture of N-ethyl-N’-[(dimethylamino)-
propyl]carbodiimide (EDC) and N-hydroxysuccinimide (NHS) in pH 7.4 buffer solution for 30 
min, followed by the injection of antibody AB9234 (10 µL of AB9234 was diluted with 600 µL 
of pH 5.0 sodium acetate buffer, injected at the rate of 10 µL per minute). Anti-amyloid oligomer 
antibody AB9234 was immobilized on the first gold sensor CM5 chip flow cell, and the second 
flow cell is used as a reference (without immobilization of AB9234). Antibody cdk5, a negative 
control, was immobilized on the third flow cell, and the fourth flow cell had no immobilization 
(used as a reference). The resulting AB9234 bound sensor chip (and the cdk5 bound chip) was 
used in the SPR studies.  The reference cells were prepared similarly but without the addition of 
AB9234 or cdk5 for correction of background bindings.  A running buffer solution consisting of 
10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.05% surfactant P20, pH 7.4, was used as a 
washing solvent between injections of reagents, antibody, Aβ42 oligomers, and CP2.  After 
immobilization of the antibody, a solution of Aβ42 oligomers (prepared by incubation of a 10 
µM solution of Aβ42 monomer in pH 7.4 PBS buffer for 24 h at 4oC; formation of small Aβ42 
oligomers were confirmed by AFM) was injected to the cell, and binding was observed.  To the 
bound AB9234-Aβ42 oligomer, a solution of CP2 (40 µM in the aforementioned running buffer) 
was injected followed by washing with the running buffer solution.  The amounts of immobilized 
antibody, bound Aβ42 oligomers and CP2 were determined based on the amounts of response 
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units obtained from the sensograms. The amounts of immobilization and bindings were 
calculated by the ΔRU value, obtained by subtracting the RU at the time before compound 
injection from the RU at the time just after injection of running buffer (Figure 2.14). RUs are 
equivalent to picograms and can be converted into picomol. One RU is defined to be 1 pg/mm2 
of bound protein molecules and can be converted into pmol/mm2.34 
 
 
Figure 2.14. SPR sensogram of the in real-time binding of CP2 to Aβ42 oligomers-AB9234 
antibody complex. The first two injections showed the immobilization of anti-amyloid oligomer 
antibody, the following five injections were Aβ42 oligomers, and the last injection was CP2. 
Lower concentrations of Aβ42 were used in the first four injections and higher concentration of 
Aβ was used in the fifth injection to ensure that the immobilized antibody was bound with the 
oligomer. 
 
2.6.2.4 Result and discussion 
SPR has been used extensively to study the interaction of peptides and proteins with other 
peptides and small organic molecules. In search of potential amyloid beta inhibitors, Tjernberg et 
al. studied the binding of small peptides (called beta sheet breakers) to full length Aβ40 
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peptide.30 In general, Aβ peptide was immobilized from a solution of very low concentration (~ 
pmol/L) on a sensor chip and maintained in a pH 7.4 buffer solution. When a drug 
molecule/peptide flows through the chip and a binding occurs between the drug/peptide and Aβ-
peptide, the refractive index of the medium next to the chip will change. This is represented by a 
response unit (RU) that is equivalent to the mass of bound drug in picograms.34 We observed less 
binding of Aβ42 over Aβ40 (Figure 2.13) because of faster aggregation of Aβ42 during the 
course of the experiment. CP2 was injected and binding of TP compounds onto the gold chip 
having Aβ was observed (∆RU). TP17 was used as a negative control.  Using Biaevaluation 
software, version 3.0, analysis of sensograms was performed. The kinetic result fits the binding 
curves to a 1:1 Langmuir binding model. Whereas, 1.5 equivalents of CP2 bind to 1 equivalent 
of Aβ40 monomers and 1 equivalent of CP2 binds to Aβ42 monomers.  No interaction was 
observed for inactive TP17-Aβ peptide. The dissociation constant KD (M) is derived from the 
equation, KD = kd/ka, where kd and ka are dissociation- and association-rate constants, 
respectively. CP2 binds to Aβ40 with a high affinity (KD= 5.05 nM) as compared to Aβ42 (KD = 
269 nM).20 
On the other hand, for CP2 to Aβ42 oligomer binding studies, anti-amyloid oligomer 
antibody (AB9234, ~150 KDa MW) was immobilized onto the CM5 gold chip. Based on the 
sensogram (Figure 2.14), after two injections of the antibody, there were 0.052 pmol of 
antiamyloid oligomer antibody immobilized. After eluting the flow cells with running buffer for 
20 min to remove all unbound antibody, preformed 10 µM Aβ42 oligomers were injected (four 
injections over 100 min) into the flow cells and 0.426 pmol of Aβ42 oligomers were found to 
bind to the antibody. After washing the flow cell with running buffer for 100 min to remove any 
unbound Aβ oligomer, a solution of CP2 (40 µM) was injected and then washed with running 
buffer, 0.21 pmol of CP2 was found to bind to the antibody–Aβ oligomer complex. The data 
suggests that for each antibody, there are eight molecules of Aβ42 (based on MW of the 
monomer; ~4530) bound to the antibody, and 4 molecules of CP2 (MW ~510) bind to each Aβ42 
oligomer-antibody. Similar binding studies were also carried out by immobilizing anti-Cdk5 
antibody in one of the flow channels as a negative control, and no bindings of Aβ42 oligomers 
were found. We also found that CP2 did not bind to anti-amyloid oligomer antibody alone when 
CP2 was injected to a separate flow cell immobilized with the antibody alone. The real-time 
  99 
binding study using SPR shows Aβ42 oligomers bind to anti-amyloid oligomer antibody and 
CP2 binds to the Aβ oligomer–antibody complex.18 
 
2.3.3 Use of protein quantification assay to study the inhibition of aggregation of Aβ  
with and without tricyclic pyrone molecule CP2 
 
2.3.3.1 Introduction and background  
Conversion of soluble, non-toxic Aβ monomers aggregate to insoluble toxic, beta sheet 
fibrils play a crucial role in pathology of AD. Any compound that either inhibits or slows down 
the kinetics of aggregation can be screened as a potential therapeutic agent for AD. Studies have 
shown that in terms of toxicity, concentration plays a very crucial role and Aβ is toxic even in 
nanomolar range.20 The Pierce Micro BCATM protein assay reagent kit has been used for 
quantitation of amyloid beta protein.35 The micro BCA reagent kit can quantify protein up to 0.5-
20 µg/mL of the sample.36 This quantification experiment utilized bicinchoninic acid (BCA) as a 
detection reagent for Cu+1 which is formed, when Cu+2 is reduced by the protein in alkaline 
environment. A purple colored solution is formed when two molecules of BCA chelates with one 
molecule of Cu+1 and this complex exhibits a strong absorbance at 530-590 nm wavelength.    
 
2.3.3.2 Inhibition of aggregation of Aβ40 and Aβ42 with CP2  
A Micromax RF refrigerated microcentrifuge (Thermo Electron Co., Fisher Scientific, 
Pittsburgh, PA) and a UV-Vis spectrometer (Shimadzu UV-120-02; Columbia, MD) were used 
for the experiment. Prior to the experiment, synthetic Aβ40 and Αβ42 (0.2 mg in 200 µL) were 
dissolved in hexafluoroisopropanol (HFIP), a low polar solvent that stabilizes the α-helix 
structure and disrupts inter-strand hydrogen bonding between the beta sheets. Sample was kept at 
25°C for 48 h, and after which HFIP was allowed to evaporate at 25°C. Four different 
concentrations of Aβ peptides, 30, 40, 50, 60 µM for Αβ40, and 10, 20, 30, 40 µM for Αβ42 
were freshly dissolved in pH 7.4 PBS buffer (500 µL) and treated each with 500 µL of freshly 
prepared Micro BCATM reagent. The solutions were incubated at 60ºC for 30 minutes, cooled to 
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25ºC, and absorbance was measured using a UV spectrometer at 569 nm wavelength (a BCA 
reagent was used as a reference) within 10 minutes.  Linear correlations (Αβ40 & 42 with and 
without CP2; 2 equivalents) between the absorbance and concentration were obtained (Graph 
2.1).18 Once the linear correlation was observed, Monomeric Aβ40 and Aβ42 peptides were 
treated with 2 equivalents of CP2 separately for 1 week at 25ºC, and each day the concentrations 
of Aβ40 and Aβ42 peptides were quantified using a micro BCATM protein assay reagent kit and 
results are summarized in Figure 2.15.18 
 
 
 
Graph 2.1. Correlations of concentrations of monomeric Aβ40 and Aβ42 separately versus UV 
absorbance with and without CP2 using Micro BCATM protein assay reagent kit. Left panel: 
Aβ40, diamond is Aβ40 with CP2 and square is Aβ40 without CP2; Right panel: Aβ42, triangle 
is Aβ42 with CP2 and circle is Aβ42 without CP2. 
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Figure 2.15. Quantification of soluble Aβ40 and Aβ42 peptide separately in PBS buffer (pH 7.4) 
at 25°C over 7 days using a micro BCATM protein assay reagent kit in the absence (marked in 
square for Aβ40 and circle for Aβ42) and presence (marked in diamond for Aβ40 and triangle 
for Aβ42) of 2 equivalents of CP2. 
 
2.6.3.3 Result and discussion 
We have already observed, by AFM and SPR spectroscopy, that CP2 binds to Aβ 
monomers and inhibit its aggregation. Also, CP2 binds to toxic Aβ oligomers and protofibrils 
and disaggregates them to non-toxic monomers (by AFM). Using Micro BCATM protein assay 
kit, we investigated whether CP2 inhibits Aβ fibril formation in PBS buffer solution (pH 7.4) 
over time at 25ºC. In the absence of CP2, we found ~73% of Aβ40 and ~43% of Aβ42 in the 
solution after 1 week. On the other hand, in the presence of two equivalents of CP2, there was 
~88% and ~81% of Aβ40 (Table 2.1) and Aβ42 (Table 2.2), respectively that remained in the 
solution after 1 week of incubation. The data shows that CP2 inhibits the fibril formation, which 
is in agreement with the results of the inhibitions of aggregation of Aβ peptides (vide supra), as 
further aggregation of oligomers leads to protofibrils and fibrils.18 
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Table 2.1. Amount of Aβ40 peptide (µM) over 7 days at 25ºC in PBS buffer (pH 7.4) at 25ºC 
with and without CP2 (two equivalents) determined by micro BCATM protein assays. 
 
 
Table 2.2. Amount of Aβ40 peptide (µM) over 7 days at 25ºC in PBS buffer (pH 7.4) at 25ºC 
with and without CP2 (two equivalents) determined by micro BCATM protein assays. 
 
2.3.4 Use of circular dichroism (CD) spectroscopy to study the inhibition of 
aggregation of Aβ  with and without tricyclic pyrone molecule CP2 
2.3.4.1 Introduction and background 
Circular dichroism helps in studying the real time secondary structure of the protein  
(Figure 2.16).37 It is known that Aβ aggregation involves the transformation of soluble 
unordered α-helix/ random coil to β-sheet rich conformation. Numerous reports have shown the 
use of CD spectroscopy to study the kinetics of Aβ aggregation pathway.38-40 In general, most 
CD studies performed so far have used fluorinated solvents such as trifluoroethanol (TFE) and 
hexafluoroisopropanol (HFIP). Since fluorinated solvents promote intramolecular hydrogen 
bonding, which indicates that stable α-helix conformation is intramolecular and β-sheet structure 
are intermolecular. TFE and HFIP are weaker proton donors than water and thus promote 
structure formation by intramolecular hydrogen bonding rather than intermolecular hydrogen 
bonding with the solvent. Barrow et al. performed detailed studies into the structure and kinetics 
of Aβ(39-43) aggregation in solution phase and concluded that the Aβ peptide adopts a mixture 
of random coil, α-helix and β-sheet with the relative ratio depending on the solvent composition, 
concentration of peptides, temperature, pH etc.41 It was observed that increasing the percentage 
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of TFE favors the formation of α-helix and random coil and a maxima was observed in 90% 
trifluoroethanol (TFE). Similar results were obtained in hexafluoroisopropanol (HFIP). We also 
obtained the similar results for Aβ42 as shown in Figure 2.17. 
 
 However, for real time in vitro inhibitors studies, use of fluorinated solvent 
(HFIP) is not a suitable solvent due to its low volatility. It was also found that the morphology 
and stability of soluble oligomers are different in HFIP when compared with aqueous buffer.42 
Recently, Andrisano et al. developed a highly reproducible in vitro assay and validated it by 
studying different synthesized and commercially available amyloid inhibitors.43 We used their 
published protocol to study the kinetics of Aβ42 aggregation and effect of CP2 on the 
inhibition/stabilization of α-helix/ random coil secondary conformation of Aβ42.   
 
 
Figure 2.16. CD spectrum of different conformations of Aβ peptide.37 
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Figure 2.17. CD spectrum showing the effect of TFE on Aβ42 peptide. 
 
2.3.4.2 Study of inhibition of aggregation of Aβ42 with CP2 (1.25 equivalents) 
A Jasco J-815 Spectropolarimeter CD instrument (JASCO; Easton, MD) and a quartz cell 
(0.1 cm length; 200 µL internal volume) were used to record CD spectra in a spectral range of 
190 – 260 nm, 1 nm data pitch, 1 nm bandwidth, and at 50 nm/min scan speed. A solution of 
Aβ42 (40 µM) in phosphate buffer solution containing NaCl, Na2CO3, NaOH, and acetonitrile 
was prepared according to the reported method43 to monitor Aβ42 solution structure in the 
absence and presence of 1.25 equivalents of CP2 over 48 h at 25ºC in a time course manner. In 
order to remove already preformed aggregates, Aβ42 (0.12 mg) was dissolved in 
hexafluoroisopropanol (HFIP; 200 µL), a low polar solvent that stabilizes the a-helix structure 
and disrupts inter-strand hydrogen bonds between of the beta sheet, by brief sonication and 
vortexing, kept at 25°C for 48 h, and HFIP was evaporated at 25°C. The resulting Aβ42 was re-
dissolved in a freshly prepared mixture (70 µL) of CH3CN/Na2CO3 (0.3 mM)/NaOH (0.25 M) 
(48.3:48.3:3.4, v/v/v) by brief sonication and vortexing providing an alkaline solution of Aβ42 
(0.38 mM). An aliquot (30 µL) of the Aβ42 solution was diluted with phosphate buffer saline 
(PBS; 0.25 mL) solution to give a 40 µM solution of Aβ42 in phosphate buffer (7.7 mM) that 
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contained NaCl (8.9 mM), Na2CO3 (15.5 mM), NaOH (0.91 mM), and 5.1% acetonitrile. CP2 
(1.25 equivalents; 10 µL of 1.5 mM in PBS-ethanol, 9:1) was added to 280 µL of the above 
Aβ42 (40 µM) solution, and CD spectra were recorded at regular interval over 48 h. The control 
solutions that contained the above incubation buffer with and without CP2 were prepared and 
their contributions were subtracted in the CD spectra of Aβ42 with and without CP2, 
respectively (Figure 2.18). Although CP2 can interfere with the experiments, 1.25 equivalents of 
CP2 alone showed only a small absorption and did not change the overall shape of Aβ42. To 
follow Aβ42 conformational changes and inhibition studies with CP2, the CD wavelength at 215 
nm (beta sheet structure) was plotted verses the time of incubation (Figure 2.19).18 
 
 
Figure 2.18. CD spectra of Aβ42 (40 µM) in phosphate buffer (7.7 mM) containing NaCl (8.9 
mM), Na2CO3 (15.5 µM), NaOH (0.91 mM), and 5.1% acetonitrile solution with and without 
CP2 over 48 h. The control solutions that contained the above incubation buffer with and without 
CP2 were prepared and their contribution was subtracted in the CD spectra. Left panel: Aβ42 
alone; 0 h: black; 9 h: light blue; 19 h: green; 21 h: dark blue; 45 h: brown; and 48 h: red. Right 
panel: Aβ42 + CP2 (1.25 equivalents); 0 h: black; 9.5 h: light blue; 15.5 h: green; 20 h: dark 
blue; 23 h: brown; and 48 h: red. 
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Figure 2.19. Trend of β-sheet content over time: circle is Aβ42 alone and square is Aβ42 + CP2. 
 
2.3.4.3 Results and discussion 
It is accepted that Aβ undergoes conformational changes or misfolding from random 
coil/α-helix to β-sheet structure, resulting in oligomerization and insoluble fibrils formation.43,44 
CD spectroscopy offers a real-time monitoring of protein conformations in aqueous solution.44 A 
PBS buffer solution containing Na2CO3-NaOH-acetonitrile was established43 recently to study 
Aβ conformational changes in the presence of Aβ42 inhibitors and marketed drugs for AD 
treatment using CD. Hence, the same buffer solution was used to examine whether CP2 
maintains Aβ42 random coil/α-helix structures and blocks β-sheet formation over times using 
CD spectroscopy. Figure 2.18, left panel, shows Aβ42 conformational changes in the absence of 
CP2 over 48 h, in which CD value at 198 nm (random coil structure) gradually decreased over 
time and 215 nm (β-sheet) value increased. On the other hand, in the presence of 1.25 
equivalents of CP2 (Figure 2.18, right panel), although band at 198 nm decreased slightly due 
to some unknown reason, CD value at 215 nm remains unchanged. In term of the kinetics of self-
aggregation, a plot of CD values at 215 nm versus time is shown in Figure 2.19. Kinetics 
proceeds in three phases: a lag phase with significant conformation change (until 0-9 hours), an 
exponential phase where there is rapid increase in aggregation (10-32 hours) followed by a 
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plateau phase (after 32 h), where majority of the conformation is beta sheet. No such aggregation 
pattern was observed in the presence of CP2. The results imply that CP2 stabilizes Aβ42 random 
coil/α-helix structures and blocks β-sheet formation. The intensity at 198 nm of Aβ42 peptide 
plus CP2 is weaker than that of Aβ42 alone because the solution of Aβ-CP2 is slightly diluted 
compared with that of Aβ alone (from the addition of a solution of CP2 in PBS) and the 
contribution of the CD graph of CP2 (control) was subtracted from the observed Aβ-CP2 
graph.18 
 
2.4 Conclusion 
 
Amyloid Aβ aggregation is the main culprit in AD. Reducing the levels of intracellular 
Aβ, preventing Aβ aggregation, and eliminating the existing Aβ aggregates have been proposed 
for treatment of AD. AFM studies demonstrated that tricyclic pyrone compound CP2 inhibits Aβ 
aggregation and disaggregates Aβ40 and  Aβ42 oligomers and protofibrils as well.  SPR 
spectroscopy and protein quantification assay studies showed that CP2 binds to Aβ42 monomer 
and oligomers. CD studies revealed that CP2 stabilizes the random coil/α-helix structures of 
monomeric Aβ42 peptide in PBS buffer, which leads to the inhibition of aggregate formation. 
Protein quantification assay results suggested that CP2 not only disaggregates Aβ oligomers but 
also inhibit fibril formation.  
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CHAPTER 3 -  Biological evaluation of tricyclic pyrone and 
pyridinone compounds: in vitro and in vivo studies 
 
 3.1 Introduction 
 
Alzheimer disease (AD) is most common cause of dementia and is considered one of the 
leading causes of death worldwide. AD is a progressive neurodegenerative disorder characterized 
by memory loss and other cognitive disabilities. In AD patients, the cognitive decline is 
accompanied by impaired performances of daily activities, behavior, speech etc. AD affects 
patient’s life at home and at work. The main pathophysiological hallmarks of AD are 
extracellular deposits of amyloid plaques formed by aggregated beta-amyloid (Aβ) peptide and 
intracellular neurofibrillary tangles (NFTs) composed of filamentous aggregates of 
hyperphosphorylated tau protein in the brain. This Aβ peptide is derived from the processing of 
large amyloid precursor protein (APP), a transmembrane protein by different enzymes. Although 
the etiology of AD is very complex and not yet fully resolved, numerous studies have shown that 
amyloid plays a central role in the neurodegeneration in AD. This hypothesis is supported by 
results indicating that amyloid aggregates are toxic to neuronal cell in culture and toxicity is 
directly linked to the extent of Aβ aggregation. Recently, it is reported that soluble small 
oligomeric intermediates rather then insoluble fibrils are primary toxic species in AD.1 In this 
chapter, I will discuss in vitro biological activity of different tricyclic pyrone molecules using 
MC6 cell assay and effectiveness of tricyclic pyrone molecule CP2 in vivo activity on 5X FAD 
(familial alzheimer disease) transgenic mice.    
 
3.2 Background 
 
Aβ aggregation is widely accepted as the first pathological process in AD. Several 
findings support this theory.  A number of genes found to be mutated in AD patients are related 
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to the biology of Aβ such as the gene for APP on chromosome 21, the gene for apoE4 on 
chromosome 19, and genes for PS1 and PS2 on chromosomes 14 and 1, respectively.2 Also, Aβ 
is proved to be toxic to neuronal cell even in nanomolar concentration and causes death via 
membrane lipid peroxidation, which impairs the function of membrane ion-motive ATPases, 
glucose and glutamate transporters, leading to membrane depolarization, excessive Ca2+ influx, 
and mitochondrial dysfunction.3 It is believed that any molecule that either inhibits aggregation 
or disaggregate preformed oligomers can serve as an attractive therapeutic target for AD. For 
successful screening of organic compounds, an efficient and reproducible screening model is a 
must. So far, limited cell culture models have shown a convincing and reproducible linkage 
between the intracellular Aβ aggregation and the cell death. This hinders the screening for 
various potentially therapeutic organic molecules. Recently, a screening model using primary 
neurons from Tg2576 APP transgenic mice has shown Aβ oligomer accumulations but 
preparation of this model is very time-consuming. Due to toxicity issues detection of 
aggregations is observed by electron microscopy.4 On the other hand, MC65 cell line can be 
conveniently used to screen potential bioactive compounds.5-7 MC65 is a human neuroblastoma 
cell line that conditionally expresses C99, a 99 amino acid residue carboxy terminal fragment 
derived from amyloid precursor protein after cleavage by the beta secretase enzyme. C99 is 
cleaved by γ-secretase enzyme leading to the generation of Aβ ( Figure 3.1). Following the 
transgene induction, significant loss of cell viability was observed after 72 h. Compared with the 
method described by Takahashi et al. MC65 cells are easily propagated and cell toxicity is 
measured quantitatively by simple 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay.6 
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Figure 3.1. Schematic representation of C99 expression. 
 
3.3 MC65 cell death is related to the intracellular generation and aggregation 
of Aβ  
 
In neuronal cells, generation and aggregation of Aβ is believed to have the toxic effect. 
Intracellular aggregation of proteins is being linked to neurodegenerative processes. The 
mechanism by which intracellular Aβ protein misfolds, aggregates and become toxic is complex 
and is poorly understood. The MC65 cell model linked the neuronal cell death to the toxicity of 
intracellular Aβ generation. Western blot analysis demonstrated the predominant formation of 
dimer, tetramer and pentamer aggregates after 24 h as shown in Figure 3.2. No monomeric Aβ 
was observed by Tricine gel analysis. The C99 was induced by removal of Tetracycline (TC). At 
indicated times, the cells were homogenized. Cellular proteins (5 µg protein each) were 
subjected to Tris/tricine sodium dodecyl sulfate–polyacrylamide gel electrophoresis and western 
blot analysis with antibody 6E10 (for Aβ1–17). Aβ Standard, synthetic Aβ40 and Aβ42, served 
as standard Aβ monomer peptides.8 
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Figure 3.2. MC65 cell death is dependent upon Aβ generation and closely related to Aβ 
aggregation into Aβ-Oligomeric complexes. 
 
 
In order to confirm the generation and toxicity of Aβ intracellularly, MC65 cells were 
treated with L-685 458, a highly specific γ-secretase inhibitor. No Aβ generation was observed 
(figure 3.3A). L-658 458 also inhibits the aggregate formation in a dose dependent manner 
(Figure 3.3B). Since the p8 (8 Kda) band is partially reduced by a γ-secretase inhibitor, it 
indicates that it is not entirely composed of Aβ peptide.8 The γ-secretase results indicated that 
MC65 cell death is dependent on the production of Aβ. The ELISA quantification suggested that 
both L-685 458 and CP2 reduced Aβ oligomeric formation.  
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Figure 3.3. Treatment of MC65 cells with TP compounds and a γ-secretase inhibitor, L-685 458 
(A) MC65 cells: –TC, without TC to induce C99 expression; +TC, with TC to suppress C99 
expression. n = 3, **p < 0.001 compared with the –TC group. (B) L-685 458 of indicated 
concentrations was added at the same time as TC removal. Cellular proteins from 24 h cultures 
were analyzed by western blot using 6E10. 
  
CP2 molecule target Aβ peptide and the dose independent effect of CP2 on Aβ was 
studied and was compared with TP17 (a negative control) (Figure 3.5). Without CP2, Aβ 
aggregates were observed. Whereas, the addition of CP2 lowered the formation of higher 
molecular weight cellular Aβ oligomer aggregates. A lower effect was observed for N9’ analog 
and no effect was observed for TP17 (Figure 3.4A). In addition, a dose dependent study of CP2 
was carried out by removal of TC and different concentrations of CP2 were added (Figure 
3.4B).8 
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Figure 3.4. Dose dependent study of CP2. CP2 inhibits the formation of Aβ-OCs. (A) MC65 
cells were treated with the indicated compounds for 24 h (2 µM N9’- analog and TP17 were 
used). Western blot of cellular proteins was analyzed with 6E10 (B) MC65 cells were treated 
with TC or without TC, but with the indicated concentrations of CP2 for 24 h. Cellular proteins 
were analyzed by western blots using 6E10. 
 
 
We observed that tricyclic pyrone molecule CP2 ameliorates Aβ toxicity and reduces the 
levels of intracellular Aβ oligomers. Compound CP2 can be easily modified to produce a series 
of new compounds. Possible modifications include functionalization of methyl group, C10 
double bond, substitute adenine with other heterocycles, replacement of oxygen at position 2 
with nitrogen, pyranoquinoline and pyranoisoquinoline etc. (Chapter 1). This structure activity 
relationship (SAR) can help us elucidate the mechanism of inhibition of aggregation.   
 
3.4 Tricyclic pyrone and pyridinone molecules inhibit the formation of Aβ  
oligomers and protect MC65 cell death 
 
Compounds that protect cell death induced by the intracellular toxic Aβ oligomers can be 
further used for the drug development in Alzheimer’s disease. We have screened several TP 
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compounds (Figure 3.5 and Figure 3.6) using the MC65 cell assay (Figure 3.7 and Table 3.1). 
MC65 cells were grown in the presence of 1 µg/ml tetracycline (TC).5 The cell toxicity was 
induced by the removal of TC to induce C99 expression. To do so, the cells were washed 
extensively with phosphate buffer (PBS), and plated on a 96-well plate at a density of 2 x 105 
cells/cm2 in Opti-MEM (without phenol-red) from Gibco/BRL (Carlsbad, CA).  For testing the 
protective effect of various TP analogs, various doses of TP compound were added to culture 
media without TC.  After incubation for 72 h, the cell viability was determined using a 
colorimetric MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, the 
results of which were comparable to data obtained using counts of viable cells based on trypan 
blue exclusion and the LIVE/DEAD assay.8-9 Different batches of MC65 cells produce small 
variations in the activities. Three batches were used to study these compounds and the average of 
the EC50 of different TP analogs is summarized in Table 3.1.10 
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 Tricyclic pyrone compound CP2 bearing a strong MC65 neuroprotective activity 
(EC50 = 0.15µM) and a low toxicity (Figure 3.7).8 Both CP2 (R and S configuration, N3’ analog) 
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have similar MC65 neuroprotective effect, whereas the N9’ analog is less active with EC50 
around 3.0 µM.  N10’ analog and TP17 are inactive thus can be used as a control for future 
experiments. 
 
Figure 3.7. MC65 protection assay for different TP compounds. L-685 458 of indicated 
concentrations was added at the same time as TC removal. At 72 h, viability was assessed by 
MTT assay. Data are expressed as mean percentage viability (n = 7) with parallel +TC cultures 
set at 100% viability. Error bars represent standard error. ***p < 0.001, **p < 0.01, compared 
with untreated –TC controls. 
 
  
Compound EC50 (µM) Compound EC50 (µM) 
2 0.31 ± 0.03 45 6.92 ± 0.69 
29 3.0 ± 0.30 43 8.30 ± 0.83 
38 1.95 ± 0.20 44 1.38 ± 0.14 
40 0.93 ± 0.09 59 0.35 ± 0.03 
47 0.86 ± 0.09 52 Inactive 
41 Inactive 53 2.49 ± 0.25 
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46 Inactive 56 1.25 ± 0.13 
34 0.31 ± 0.04 
Table 3.1. TP compounds and their IC50 inhibitory activities. 
 
Compound 38 has a structure similar to 2 (CP2) containing a double at C12 is 6 folds less 
active. Substituting the adenine of CP2 with other heterocycles lowers the activity. Compounds 
41 and 46 are surprisingly inactive. Simple tricyclic pyridinone 56, which have a nitrogen atom 
at position 2, possesses an EC50 of 1.25 µM, and its adenine derivative 59 has similar EC50 
activity as that of CP2. The Linear fused pyranoquinoline (52) is inactive however, the L-shape 
fused pyranoisoquinoline (53), lacking an adenine unit, is 8 fold less active then CP2. Further 
investigation is required on the synthesis of N2 and N5 containing tricyclic pyrones.  
  
3.5 Tricyclic pyrone molecule CP2 penetrates MC65 cell  
 
Previous experiments have shown that compound CP2 interacts with the intracellular and 
the extracellular Aβ. Rapid accumulation of CP2 was observed inside the cells as well as on the 
cell surface when we incubated the radiotracer [14C]CP2 molecule to the MC65 cells (figure 
3.8). Radiotracer [14C]CP2 (0.04 µCi) was added to the cell culture wells of 2.5 X 106 cells and 
was incubated for the indicated period of time. The cells were scraped and spun down. Cell 
pellets were washed with ice-cold phosphate buffer and trypsinized. The supernatant was kept as 
‘trypsinizable cell surface’, and pallets were called ‘non-trypsinizable intracellular fraction’. 
Fractions were subjected to scintillation counting. Results showed that compound CP2 easily 
penetrated the cells, interacted/binded to the Aβ monomers and Aβ oligomers, and disrupted 
aggregation by either binding to the Aβ peptide or by changing the conformation of the peptide 
or by some unknown complex mechanism (figure 3.8).8 
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Figure 3.8. CP2 rapidly accumulates inside cells. MC65 cells were incubated with [14C]CP2 for 
the indicated periods of time, washed, and the cell-associated counts that were trypsinizable from 
cell pellets (cell surface CP2, empty circles) and those remaining in cells after trypsinization 
(intracellular CP2, filled circles) were quantified. Expressed values are quantities of CP2 
calculated from the radioactivity of 105 cells. 
 
3.6 In vivo studies of CP2 on 5X FAD mice 
3.6.1 Introduction and background 
 
Amyloid plaque in the brain is mainly composed of Aβ peptide. Also, a strong genetic 
association between early-onset familial alzheimer disease (FAD) and Aβ peptides is well 
established.11-13 Association of Aβ42 and FAD favors the causative role for Aβ42 in the etiology 
of AD.14 Dr. Vasser et al. developed a rapid AD amyloid model of transgenic mice where five 
different FAD mutations were expressed [APP K670N, M67IL (Swedish) + I716V (Florida) + 
V717I (London) and human PS1 M146 l + L286V]. These “5X FAD” transgenic mice develop 
cerebral amyloid plaque and gliosis at 2 months of age. Aβ42 aggregates and reduced synaptic 
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markers are the characteristics of 5X FAD transgenic mice.14 Interestingly, accumulation of 
intraneuronal Aβ42 was observed before the amyloid plaque formation.14 Accumulation of 
intraneuronal Aβ was observed in the brain of AD mice.15-16 We are interested in studying the 
efficacy of CP2 in 5X FAD transgenic model. Our collaborator Dr. Lee-Way Jin in UC Davis 
Health System, Sacramento, CA, has conducted all the in vivo experiments.  
 
3.6.2 Experimental for in vivo studies 
 
The UC Davis Animal Care and Use Committee approved all animal procedures followed 
on animals. 5X FAD mice were obtained from Dr. Robert Vassar, Department of Cell and 
Molecular Biology, Northwestern University.12 Bioactive compound CP2 or an equivalent 
amount of DMSO (solvent; mock) was dissolved in 100 µL of artificial cerebrospinal fluid to 
make a working solution of 100µM concentration. The solution was transferred into osmotic 
mini-pumps (Alzet, Cupertino, CA). A reported procedure to implant the pump was followed.17 
Three-month-old 5x FAD transgenic mice were anesthetized with an intraperitoneal (i.p.) 
injection of Ketamin (100 mg/Kg body weight) with Xylazine (10 mg/Kg body weight). A brain-
infusion cannula (brain infusion kit #3, Alzet) was stereotaxically positioned (antero-posterior, 
0.7 mm; mediolateral, 1.5 mm; dorsoventral; 3 mm to Bregma) by cementing with Loctite 454 
(Alzet, Cupertino, CA). This cannula was then connected to the subcutaneously implanted 
osmotic mini-pump (Alzet model 1002). Mice were infused (n = 6 for each group) at a flow rate 
of 0.25 µL/h for 2 weeks of CP2 or vehicle (DMSO). After 2 weeks, the mice were sacrificed 
and their brains were removed and snap frozen for Aβ42 ELISA.18 
 
3.6.3 Aβ42 ELISA 
 
The corresponding 1 mm-thick fresh frozen mouse brain sections containing 
hippocampus and subiculum were homogenized in 300 µL of radioimmune precipitation assay 
(RIPA) buffer containing protease inhibitors mixture solution. The homogenates were sonicated 
briefly then incubated for 20 min at 4°C. The RIPA insoluble fraction from brain homogenate 
  125 
was obtained after centrifugation at 100,000 x g. The pellet was resuspended in 300 µL of 70% 
formic acid (FA) and then incubated for 30 min at 4°C. FA soluble fraction was obtained by 
100,000 x g centrifugation. The FA extracts were neutralized by diluting 1:20 in 1 mole/L Tris 
buffer (pH 11). The Aβ42 concentration in each sample was determined by Aβ42 specific 
sandwich ELISA following the protocol of the manufacturer (IBL, Minneapolis, MN). All 
readings were in the linear range of the assay. The average of the duplicates was determined, and 
then the mean and standard error for each group of mice was calculated. The values were 
expressed in nanograms of Aβ per milligram of protein. The statistical significance of 
differences between groups was examined by t-test, using the SigmaStat 3.1 program (Systat Inc. 
Point Richmond, CA).18 
 
3.6.4 Results and discussion 
 
Neurons in these transgenic mice were engineered to generate a large amount of Aβ42, 
which results in robust Aβ accumulation and aggregation in brain.14 Histologically detectable 
amyloid depositions begin by 2 months, especially in hippocampus and subiculum, and increase 
sharply between 2-4 months. We infused 100 µM CP2 or mock solution (DMSO alone) into 
cerebral ventricles of 3-month-old 5x FAD mice for two weeks at a speed of 0.25 µL/h 
(equivalent to approximately 370 ng per day). At the completion of this treatment, the mice were 
sacrificed and brains removed for quantification of Aβ levels by sandwich ELISA. The brains 
slices were extracted sequentially by RIPA and FA respectively. Previously, we found that the 
majority of Aβ in 5X FAD brain resides in the RIPA-soluble and FA-soluble fractions, which are 
roughly equivalent to the non-fibrillar and fibrillar Aβ species respectively.19 CP2 treatment 
resulted in a 40% reduction of RIPA-soluble Aβ and a 50% reduction of FA-soluble 
Aβ (Figure 3.9). Thus, in a mouse model with perhaps the most robust Aβ42 production among 
all AD models, a short 2-week treatment of CP2 showed a promising anti-Aβ effect.18 
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Figure 3.9. CP2 treatment reduces the level of cerebral Aβ. Brains from mice treated with CP2 
or mock solution were sequentially extracted with RIPA and FA. Aβ42 levels in the RIPA and 
FA extracts (RIPA soluble and FA soluble, respectively) were measured by ELISA. Aβ levels 
were expressed in nanograms per milligram of brain protein. CP2 reduced the levels of both 
RIPA and FA soluble Aβ42. Error bars represent standard error. n = 6. The p values were 
obtained by comparing the two groups using t-test. 
 
3.7 Conclusion 
The neurotoxicity of amyloid β-protein is widely considered as one of the fundamental 
causes of neurodegeneration. In our laboratory, we synthesized a series of tricyclic pyrones and 
pyridinones and screened these compounds against Alzheimer’s disease, which leads to the 
discovery of compound CP2, a small molecule that easily penetrates into the cells. Our data 
suggests that CP2 not only inhibits the Aβ aggregation but also disaggregates the preformed 
toxic small oligomers and protofibrils. Other than cell permeability character, CP2 also favors 
blood brain barrier passage. Our results strongly demonstrate that Aβ oligomeric complexes 
(Aβ-OC’s, tetramers and pentamers) are the major culprit causing MC65 cell death. We believe 
that CP2 is a novel small compound, which has the ability to inhibit intracellular Aβ aggregation. 
Treatment of 5X familial Alzheimer’s disease mice with CP2 over the period of two weeks 
resulted in 40% decrease in non-fibrillar aggregates and a 50% in decrease in fibrillar Aβ 
species. 
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Appendix: 1H-NMR spectra, 13C-NMR spectra, MS spectra, 2D-NOESY, 2D-
COSY, 2D-HMBC, 2DHSQC  
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